Document:

<PAGE>

                                                                    Exhibit 4.11

                        INHALE THERAPEUTIC SYSTEMS, INC.
                            (a Delaware corporation)

                                  $200,000,000
                  5.00% Convertible Subordinated Notes due 2007

                               PURCHASE AGREEMENT

                                                                February 2, 2000

MERRILL LYNCH & CO.
Merrill Lynch, Pierce, Fenner & Smith
                Incorporated
Deutsche Bank Securities Inc.
Lehman Brothers Inc.
U.S. Bancorp Piper Jaffray Inc.
c/o Merrill Lynch & Co.
North Tower
World Financial Center
New York, New York 10281-1209

Ladies and Gentlemen:

         Inhale Therapeutic Systems, Inc., a Delaware corporation (the
"Company"), confirms its agreement with Merrill Lynch & Co., Merrill Lynch,
Pierce, Fenner & Smith Incorporated ("Merrill Lynch") and each of the other
Initial Purchasers named in SCHEDULE A hereto (collectively, the "Initial
Purchasers", which term shall also include any initial purchaser substituted as
hereinafter provided in Section 11 hereof), for whom Merrill Lynch and Deutsche
Bank Securities Inc. are acting as representatives (in such capacity, the
"Representatives"), with respect to the issue and sale by the Company and the
purchase by the Initial Purchasers, acting severally and not jointly, of the
respective principal amounts set forth in said SCHEDULE I of $200,000,000
aggregate principal amount of the Company's 5.00% Convertible Subordinated Notes
due 2007 (the "Firm Notes"), and with respect to the grant by the Company to the
Initial Purchasers, acting severally and not jointly, of the option described in
Section 2(b) hereof (the "Option") to purchase all or any part of an additional
$30,000,000 principal amount of the Company's 5.00% Convertible Subordinated
Notes due 2007 to cover over-allotments, if any (the "Optional Notes" and,
together with the Firm Notes, the "Notes").

         The Notes will be convertible into fully paid, nonassessable shares of
common stock of the Company, par value $0.0001 per share (the "Common Stock"),
on the terms, and subject to the conditions, set forth in the Indenture. As used
herein, "Conversion Shares" means the shares of Common Stock into which the
Notes are convertible. The Notes will be issued pursuant to

                                       1
<PAGE>

an Indenture (the "Indenture") to be dated as of the First Delivery Date (as
defined in Section 2(a)), between the Company and Chase Manhattan Bank and Trust
Company, National Association, as Trustee (the "Trustee").

         The Notes will be offered and sold without being registered under the
Securities Act of 1933, as amended (the "Securities Act"), in reliance on
exemptions therefrom. The Company has prepared and delivered to each Initial
Purchaser copies of a preliminary offering memorandum dated January 31, 2000
(the "Preliminary Offering Memorandum") and has prepared and will deliver to
each Initial Purchaser, on the date hereof or the next succeeding day, copies of
a final offering memorandum dated February 2, 2000 (the "Final Offering
Memorandum"), each for use by such Initial Purchaser in connection with its
solicitation of purchases of, or offering of, the Notes. "Offering Memorandum"
means, with respect to any date or time referred to in this Agreement, the most
recent offering memorandum (whether the Preliminary Offering Memorandum or the
Final Offering Memorandum, or any amendment or supplement to either such
document), including exhibits thereto and any documents incorporated therein by
reference, which has been prepared and delivered by the Company to the Initial
Purchasers in connection with their solicitation of purchases of, or offering
of, the Notes.

         Holders of the Notes (including the Initial Purchasers and their direct
and indirect transferees) will be entitled to the benefits of a Resale
Registration Rights Agreement, dated the First Delivery Date, between the
Company and the Initial Purchasers (the "Registration Rights Agreement"),
pursuant to which the Company will agree to file with the Securities and
Exchange Commission (the "Commission") a shelf registration statement pursuant
to Rule 415 under the Securities Act (the "Registration Statement") covering the
resale of the Notes and the Conversion Shares, and to use its best efforts to
cause the Registration Statement to be declared effective.

         This Agreement, the Indenture, the Notes and the Registration Rights
Agreement are referred to herein collectively as the "Operative Documents".

         Capitalized terms used herein without definition have the respective
meanings specified in the Offering Memorandum.

1. REPRESENTATIONS, WARRANTIES AND AGREEMENTS OF THE COMPANY. The Company
represents and warrants to each Initial Purchaser as of the date hereof and as
of each Delivery Date (as defined in Section 2(b)) and agrees with each Initial
Purchaser, as follows:

         (a) Each of the Preliminary Offering Memorandum and the Offering
Memorandum, did not as of its respective date, and the Offering Memorandum will
not as of a Delivery Date (as defined in Section 2(b)), contain any untrue
statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which
they were made, not misleading; PROVIDED that the Company makes no
representation or warranty as to information contained in or omitted from the
Preliminary Offering Memorandum or the Offering Memorandum in reliance upon and
in conformity with written information furnished to the Company by or on the
behalf of any Initial Purchaser through the Representatives specifically for
inclusion therein.

                                       2
<PAGE>

         (b) Assuming the accuracy of the representations and warranties of the
Initial Purchasers contained in Section 6 and their compliance with the
agreements set forth therein, it is not necessary, in connection with the
issuance and sale of the Notes to the Initial Purchasers and the offer, resale
and delivery of the Notes by the Initial Purchasers in the manner contemplated
by this Agreement, the Indenture, the Registration Rights Agreement and the
Offering Memorandum, to register the Notes or the Conversion Shares under the
Securities Act or to qualify the Indenture under the Trust Indenture Act of
1939, as amended (the "Trust Indenture Act").

         (c) The Company has been duly incorporated and is validly existing as a
corporation in good standing under the laws of the State of Delaware, is duly
qualified to do business and is in good standing as a foreign corporation in
each jurisdiction in which its ownership or lease of property or the conduct of
its businesses requires such qualification (except for where the failure to be
so qualified would not have a material adverse effect on the affairs,
management, business, properties, financial condition, results of operations or
prospects of the Company, whether or not arising in the ordinary course of
business (a "Material Adverse Effect")), and has all power and authority
necessary to own or hold its properties and to conduct the businesses in which
it is engaged, as described in the Offering Memorandum; and the Company has no
subsidiaries.

         (d) The authorized, issued and outstanding capital stock of the
Company, as of September 30, 1999, is as set forth in the Offering Memorandum
under the column entitled "Actual" under the caption "Capitalization", and all
of the issued and outstanding shares of capital stock of the Company have been
duly and validly authorized and issued, are fully paid and nonassessable; none
of the outstanding shares of capital stock of the Company was issued in
violation of the preemptive or other similar rights of any securityholder of the
Company; the capital stock of the Company conforms to the description thereof
contained in the Offering Memorandum and such description conforms to the rights
set forth in the instruments defining the same; the Conversion Shares, which are
authorized on the date hereof, have been duly and validly authorized and
reserved for issuance upon conversion of the Notes by all necessary corporate
action and are free of preemptive rights; all Conversion Shares, when so issued
and delivered upon such conversion in accordance with the terms of the
Indenture, will be duly and validly authorized and issued, fully paid and
nonassessable and free and clear of all liens, encumbrances, equities or claims;
and the issuance of such Conversion Shares upon such conversion will not be
subject to the preemptive or other similar rights of any securityholder of the
Company.

         (e) The execution, delivery and performance of the Operative Documents
by the Company and the issuance of the Notes and the Conversion Shares and the
consummation of the transactions contemplated hereby and thereby will not (x)
conflict with or result in a breach or violation of any of the terms or
provisions of, or constitute a default under, any indenture, mortgage, deed of
trust, loan agreement or other agreement or instrument to which the Company is a
party or by which the Company is bound or to which any of the properties or
assets of the Company is subject, (y) result in any violation of the provisions
of the certificate of incorporation or bylaws of the Company or (z) result in
any violation of any statute or any order, rule or regulation of any court or
governmental agency or body having jurisdiction over the

                                       3
<PAGE>

Company or any of its properties or assets; and except (i) with respect to the
transactions contemplated by the Registration Rights Agreement, as may be
required under the Securities Act, the Trust Indenture Act and the rules and
regulations promulgated thereunder and (ii) as required by the state securities
or "blue sky" laws, no consent, approval, authorization or order of, or filing
or registration with, any such court or governmental agency or body is required
for the execution, delivery and performance of the Operative Documents by the
Company, and the consummation of the transactions contemplated hereby and
thereby.

         (f) The Company has all necessary corporate right, power and authority
to execute and deliver this Agreement and perform its obligations hereunder; and
this Agreement and the transactions contemplated hereby have been duly
authorized, executed and delivered by the Company.

         (g) The Company has all necessary corporate right, power and authority
to execute and deliver the Indenture and perform its obligations thereunder; the
Indenture has been duly authorized by the Company, and upon the effectiveness of
the Registration Statement, will be qualified under the Trust Indenture Act; on
the First Delivery Date, the Indenture will have been duly executed and
delivered by the Company and, assuming due authorization, execution and delivery
of the Indenture by the Trustee, will constitute a legally valid and binding
agreement of the Company enforceable against the Company in accordance with its
terms, except as the enforceability thereof may be limited by bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and other similar
laws relating to or affecting creditors' rights generally, subject to general
principles of equity and to limitations on availability of equitable relief,
including specific performance (whether considered in a proceeding in equity or
at law) and an implied covenant of good faith and fair dealing; and the
Indenture conforms in all material respects to the description thereof contained
in the Offering Memorandum and will be in substantially the form last delivered
to the Initial Purchasers prior to the date of this Agreement.

         (h) The Company has all necessary corporate right, power and authority
to execute and deliver the Registration Rights Agreement and perform its
obligations thereunder; the Registration Rights Agreement and the transactions
contemplated thereby have been duly authorized by the Company; when the
Registration Rights Agreement is duly executed and delivered by the Company
(assuming due authorization, execution and delivery by the Initial Purchasers),
it will be a legally valid and binding agreement of the Company enforceable
against the Company in accordance with its terms, except as the enforceability
thereof may be limited by bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and other similar laws relating to or affecting
creditors' rights generally, subject to general principles of equity and to
limitations on availability of equitable relief, including specific performance
(whether considered in a proceeding in equity or at law) and an implied covenant
of good faith and fair dealing, and except with respect to the rights of
indemnification and contribution thereunder, where enforcement thereof may be
limited by federal or state securities laws or the policies underlying such
laws; and the Registration Rights Agreement conforms in all material respects to
the description thereof contained in the Offering Memorandum and will be in
substantially the form last delivered to the Initial Purchasers prior to the
date of this Agreement.

                                       4
<PAGE>

         (i) The Company has all necessary corporate right, power and authority
to execute, issue and deliver the Notes and perform its obligations thereunder;
the Notes have been duly authorized by the Company; when the Notes are executed,
authenticated and issued in accordance with the terms of the Indenture and
delivered to and paid for by the Initial Purchasers pursuant to this Agreement
on the respective Delivery Date (assuming due authentication of the Notes by the
Trustee), such Notes will constitute legally valid and binding obligations of
the Company, entitled to the benefits of the Indenture and enforceable against
the Company in accordance with their terms, except as the enforceability thereof
may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and other similar laws relating to or affecting creditors' rights
generally, subject to general principles of equity and to limitations on
availability of equitable relief, including specific performance (whether
considered in a proceeding in equity or at law) and an implied covenant of good
faith and fair dealing; and the Notes conform in all material respects to the
description thereof contained in the Offering Memorandum and will be in
substantially the form last delivered to the Initial Purchasers prior to the
date of this Agreement.

         (j) Except for the Registration Rights Agreement and the Stock Purchase
Agreement, dated January 18, 1995, between the Company and Pfizer, Inc.
("Pfizer"), the Stock Purchase Agreement, dated March 1, 1996, as amended,
between the Company and Baxter Healthcare Corporation, the Restated Investor
Rights Agreement, dated April 29, 1993, as amended October 29, 1993, among the
Company and certain stockholders of the Company, the Resale Registration Rights
Agreement, dated October 13, 1999, between the Company and the initial
purchasers named therein, and the Registration Rights Agreement between the
Company and Alliance Pharmaceutical Corp., dated January 24, 2000, there are no
contracts, agreements or understandings between the Company and any person
granting such person the right (other than rights which have been waived or
satisfied) to require the Company to file a registration statement under the
Securities Act with respect to any securities of the Company owned or to be
owned by such person or to require the Company to include such securities in any
securities being registered pursuant to any registration statement filed by the
Company under the Securities Act.

         (k) The Company has not sustained, since the date of the latest audited
financial statements included in the Offering Memorandum, any material loss or
interference with its business from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree; and, since such dates, there has not been
any change in the capital stock or long-term debt of the Company or any material
adverse change in or affecting the affairs, management, business, properties,
financial condition, stockholders' equity, results of operations or prospects of
the Company, whether or not arising in the ordinary course of business, except:
(i) as described in the Offering Memorandum, (ii) any grants under the Company's
employee stock plans in accordance with the terms of such plans as described in
the Offering Memorandum, or other shares of Common Stock (or rights to receive
Common Stock) issued to service providers to the Company in the ordinary course
of business ("Authorized Grants"), (iii) operating losses incurred in the
ordinary course of business, (iv) shares of Common Stock issued in connection
with the Asset Purchase Agreement, dated October 4, 1999, between the Company
and Alliance Pharmaceutical Corp. (the "Alliance

                                       5
<PAGE>

Agreement"), (v) the issuance and sale of the Outstanding Debentures (as defined
below) or (vi) shares of Common Stock into which the Company's outstanding
6-3/4% Convertible Subordinated Debentures due 2006 are convertible (the
"Outstanding Debentures").

         (l) The financial statements of the Company (including the related
notes and supporting schedules) included in the Offering Memorandum present
fairly the financial condition and results of operations of the Company, at the
dates and for the periods indicated, and have been prepared in conformity with
generally accepted accounting principles applied on a consistent basis
throughout the periods involved. The selected financial information included in
the Offering Memorandum present fairly the information shown therein and have
been compiled on a basis consistent with that of the audited financial
statements included in the Offering Memorandum.

         (m) Ernst &Young LLP, who have certified the financial statements of
the Company included in the Offering Memorandum, whose report appears in the
Offering Memorandum, are independent accountants as required by the Securities
Act and the rules and regulations promulgated thereunder.

         (n) The Company has good and marketable title in fee simple to all real
property and good and marketable title to all personal property owned by it, in
each case free and clear of all liens, encumbrances, security interests, claims
and defects, except such as are described in the Offering Memorandum or such as
do not, singly or in the aggregate, materially affect the value of such property
and do not interfere with the use made and proposed to be made of such property
by the Company; and all real property and personal property held under lease or
sublease by the Company is held by it under valid, subsisting and enforceable
leases (or subleases, as the case may be) in full force and effect, with such
exceptions as are not material and do not interfere with the use made and
proposed to be made of such property by the Company. The Company has no notice
of any material claim of any sort that has been asserted by anyone adverse to
the rights of the Company under any of the leases or subleases mentioned above,
or affecting or questioning the rights of such the Company thereof to the
continued possession of the leased or subleased premises under any such lease or
sublease.

         (o) The Company carries, or is covered by, insurance as is customary
for companies similarly situated and engaged in similar businesses in similar
industries.

         (p) The Company owns, or possesses adequate rights to use, all material
trademarks, service marks, trade names, trademark registrations, service mark
registrations, copyrights and licenses necessary for the conduct of its
business, and has no reason to believe that the conduct of its business will
conflict with, and has not received any notice of any claim of conflict with,
any such rights of others.

         (q) The Company owns, or possesses adequate rights to use, all material
patents necessary for the conduct of its business. Except as set forth in the
Offering Memorandum, no valid U.S. patent is, or to the knowledge of the Company
would be, infringed by the activities of the Company in the manufacture, use,
offer for sale or sale of any product or component thereof as described in the
Offering Memorandum. The patent applications (the "Patent Applications")

                                       6
<PAGE>

filed by or on behalf of the Company described in the Offering Memorandum have
been properly prepared and filed on behalf of the Company; each of the Patent
Applications and patents (the "Patents") described in the Offering Memorandum is
assigned or licensed to the Company, and, except as set forth or contemplated in
the Offering Memorandum, no other entity or individual has any right or claim in
any Patent, Patent Application or any patent to be issued therefrom; and, to the
knowledge of the Company, each of the Patent Applications discloses potentially
patentable subject matter. There are no actions, suits or judicial proceedings
pending relating to patents or proprietary information to which the Company is a
party or of which any property of the Company is subject, and, to the knowledge
of the Company, no actions, suits or judicial proceedings are threatened by
governmental authorities or, except as set forth or contemplated in the Offering
Memorandum, others. The Company is not aware of, except as set forth or
contemplated in the Offering Memorandum, any claim by others that the Company is
infringing or otherwise violating any patents or other intellectual property
rights of others and is not aware of any rights of third parties to any of the
Company's Patent Applications, licensed Patents or licenses which could affect
materially the use thereof by the Company. Except as set forth in the Offering
Memorandum, the Company owns or possesses sufficient licenses or other rights to
use all patents, trade secrets, technology and know-how necessary to conduct the
Company's business as described in the Offering Memorandum.

         (r) Except as disclosed in the Offering Memorandum, the Company has
filed with the Food and Drug Administration (the "FDA") and the California Food
and Drug Branch ("CFDB") for and received approval of all registrations,
applications, licenses, requests for exemptions, permits and other regulatory
authorizations necessary to conduct the Company's business as it is described in
the Offering Memorandum; the Company is in material compliance with all such
registrations, applications, licenses, requests for exemptions, permits and
other regulatory authorizations, and all applicable FDA and CFDB rules and
regulations, guidelines and policies, including but not limited to, applicable
FDA and CFDB rules, regulations and policies relating to current good
manufacturing practice ("CGMP") and current good laboratory practice ("CGLP");
the Company has no reason to believe that any party granting any such
registration, application, license, request for exemption, permit or other
authorization is considering limiting, suspending or revoking the same and knows
of no basis for any such limitation, suspension or revocation.

         (s) The human clinical trials, animal studies and other preclinical
tests conducted by the Company or in which the Company has participated that are
described in the Offering Memorandum or the results of which are referred to in
the Offering Memorandum, and, to the knowledge of the Company, such studies and
tests conducted on behalf of the Company, were and, if still pending, are being
conducted in accordance with commonly used or appropriate experimental
protocols, procedures and controls applied by research scientists generally in
the preclinical or clinical study of new drugs; the descriptions or the results
of such studies and tests contained in the Offering Memorandum are accurate and
complete in all material respects, and the Company has no knowledge of any other
studies or tests, the results of which reasonably call into question the results
described or referred to in the Offering Memorandum; and the Company has not
received any notices or other correspondence from the FDA or any other
governmental agency requiring the termination, suspension or modification of any
animal studies or other preclinical tests, or clinical studies conducted by or
on behalf of the Company or in which the

                                       7
<PAGE>

Company has participated that are described in the Offering Memorandum or the
results of which are referred to in the Offering Memorandum.

         (t) Except as disclosed in the Offering Memorandum, there are no legal
or governmental proceedings pending to which the Company is a party or of which
any property or asset of the Company is the subject which, if determined
adversely to the Company might have a Material Adverse Effect, or which might
reasonably be expected to materially and adversely affect the consummation of
the transactions contemplated by this Agreement or the performance by the
Company of its obligations hereunder; to the Company's knowledge, no such
proceedings are threatened or contemplated by governmental authorities or,
except as set forth or contemplated in the Offering Memorandum, threatened by
others; and the aggregate of all pending legal or governmental proceedings to
which the Company is a party or of which any of its property or assets is the
subject (other than the Company's patent applications currently pending before
the U.S. Patent and Trademark Office or before any foreign governmental
authority that administers the registration of patents), which are not described
in the Offering Memorandum, including ordinary routine litigation incidental to
the business, could not reasonably be expected to result in a Material Adverse
Effect.

         (u) No event has occurred nor has any circumstance arisen which, had
the Notes been issued on such Delivery Date, would constitute a default or an
Event of Default (as such term is defined in the Indenture).

         (v) The Company is not (i) in violation of its certificate of
incorporation or bylaws, (ii) in default, and no event has occurred which, with
notice or lapse of time or both, would constitute such a default, in the due
performance or observance of any term, covenant or condition contained in any
indenture, mortgage, deed of trust, loan agreement or other agreement or
instrument to which it is a party or by which it is bound or to which any of its
properties or assets is subject or (iii) in violation of any law, ordinance,
governmental rule, regulation or court decree to which it or its properties or
assets may be subject or has failed to obtain any license, permit, certificate,
franchise or other governmental authorization or permit necessary to the
ownership of its properties or to the conduct of its business, except to the
extent that any such default, event or violation described in the foregoing
clauses (i), (ii) and (iii) would not have a Material Adverse Effect.

         (w) The Company is in compliance in all material respects with all
presently applicable provisions of the Employee Retirement Income Security Act
of 1974, as amended, including the regulations and published interpretations
thereunder ("ERISA"); no "reportable event" (as defined in ERISA) has occurred
with respect to any "pension plan" (as defined in ERISA) for which the Company
would have any liability; the Company has not incurred and does not expect to
incur liability under (i) Title IV of ERISA with respect to termination of, or
withdrawal from, any "pension plan" or (ii) Sections 412 or 4971 of the Internal
Revenue Code of 1986, as amended, including the regulations and published
interpretations thereunder (the "Code"); and each "pension plan" for which the
Company would have any liability that is intended to be qualified under Section
401(a) of the Code is so qualified in all material respects and nothing has
occurred, whether by action or by failure to act, which would cause the loss of
such qualification.

                                       8
<PAGE>

         (x) The Company is subject to the reporting requirements of Section 13
or Section 15(d) of the Exchange Act. The Company has timely and properly filed
with the Commission all reports and other documents required to have been filed
by it with the Commission pursuant to the Exchange Act and the Exchange Act
Regulations ("Exchange Act Reports"); PROVIDED, HOWEVER, that the Company makes
no such representation or warranty with respect to any statement in or omission
from the Exchange Act Reports relating, directly or indirectly, to the
conversion of any Outstanding Debentures.

         (y) The Company has filed all federal, state and local income and
franchise tax returns required to be filed through the date hereof or has
requested extensions thereof and has paid all taxes due thereon, and no tax
deficiency has been determined adversely to the Company which has had (nor does
the Company have any knowledge of any tax deficiency which, if determined
adversely to the Company, might have) a Material Adverse Effect.

         (z) There has been no storage, disposal, generation, manufacture,
refinement, transportation, handling or treatment of toxic wastes, medical
wastes, hazardous wastes or hazardous substances by the Company (or, to the
knowledge of the Company, any of its predecessors in interest) at, upon or from
any of the property now or previously owned or leased by the Company in
violation of any applicable law, ordinance, rule, regulation, order, judgment,
decree or permit or which would require remedial action under any applicable
law, ordinance, rule, regulation, order, judgment, decree or permit, except for
any violation or remedial action which would not have, or could not be
reasonably likely to have, singularly or in the aggregate with all such
violations and remedial actions a Material Adverse Effect; there has been no
material spill, discharge, leak, emission, injection, escape, dumping or release
of any kind onto such property or into the environment surrounding such property
of any toxic wastes, medical wastes, solid wastes, hazardous wastes or hazardous
substances due to or caused by the Company or with respect to which the Company
has knowledge, except for any such spill, discharge, leak, emission, injection,
escape, dumping or release which would not have or would not be reasonably
likely to have, singularly or in the aggregate with all such spills, discharges,
leaks, emissions, injections, escapes, dumpings and releases, a Material Adverse
Effect; and the terms "hazardous wastes", "toxic wastes", "hazardous substances"
and "medical wastes" shall have the meanings specified in any applicable local,
state, federal and foreign laws or regulations with respect to environmental
protection.

         (aa) There are no contracts or other documents which would be required
to be described in the Offering Memorandum if the Offering Memorandum were a
prospectus included in a registration statement on Form S-1 that have not been
so described in the Offering Memorandum.

         (bb) There is no relationship, direct or indirect, between or among the
Company, on the one hand, and the directors, officers, shareholders, customers
or suppliers of the Company, on the other hand, which would be required to be
described in the Offering Memorandum if the Offering Memorandum were a
prospectus included in a registration statement on Form S-1 that has not been so
described.

                                       9
<PAGE>

         (cc) Since the date as of which information is given in the Offering
Memorandum through the date hereof, the Company has not (i) issued or granted
any securities (other than Authorized Grants or the Old Conversion Shares), (ii)
incurred any material liability or obligation, direct or contingent, other than
liabilities and obligations which were incurred in the ordinary course of
business, (iii) entered into any material transaction not in the ordinary course
of business (other than privately negotiated transactions relating to the
conversion of any Outstanding Debentures as described in the Offering
Memorandum) or (iv) declared or paid any dividend on its capital stock.

         (dd) Except as disclosed in the Offering Memorandum, (i) there are no
outstanding securities convertible into or exchangeable for, or warrants, rights
or options issued by the Company to purchase, any shares of the capital stock of
the Company (except, in the case of options, any Authorized Grants), (ii) there
are no statutory, contractual, preemptive or other rights to subscribe for or to
purchase any Common Stock that do not by their terms terminate upon the First
Delivery Date and (iii) there are no restrictions upon transfer of the Common
Stock pursuant to the Company's certificate of incorporation or bylaws.

         (ee) The Company (i) makes and keeps materially accurate books and
records and (ii) maintains internal accounting controls which provide reasonable
assurance that (A) transactions are executed in accordance with management's
authorization, (B) transactions are recorded as necessary to permit preparation
of its financial statements and to maintain accountability for its assets, (C)
access to its assets is permitted only in accordance with management's
authorization and (D) the reported accountability for its assets is compared
with existing assets at reasonable intervals.

         (ff) Neither the Company nor any director, officer, agent or employee
acting on behalf of the Company has (i) used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful expense relating to
political activity, (ii) made any direct or indirect unlawful payment to any
foreign or domestic government official or employee from corporate funds, (iii)
violated or is in violation of any provision of the Foreign Corrupt Practices
Act of 1977 or (iv) made any bribe, rebate, payoff, influence payment, kickback
or other unlawful payment.

         (gg) No labor disturbance by the employees of the Company exists or, to
the knowledge of the Company, is imminent which might be expected to have a
Material Adverse Effect.

         (hh) The Company is not, and upon the issuance and sale of the Notes as
herein contemplated and the application of the net proceeds therefrom as
described in the Offering Memorandum will not be, an "investment company" or an
entity "controlled" by an "investment company" as such terms are defined in the
Investment Company Act of 1940, as amended.

         (ii) Assuming the accuracy of the representations and warranties of the
Initial Purchasers contained in Section 6 and their compliance with the
agreements set forth therein, the Securities will be eligible for resale
pursuant to Rule 144A. No securities of the same class (within the meaning of
Rule 144A(d)(3) under the Securities Act) as the Notes are listed on any
national

                                       10
<PAGE>

securities exchange registered under Section 6 of the Exchange Act or quoted on
an automated inter-dealer quotation system.

         (jj) None of the Company or any of its Affiliates (as defined in Rule
501(b) of Regulation D under the Securities Act ("Regulation D")) (other than
the Initial Purchasers, about which no representation is made by the Company),
has, directly or through an agent, engaged or will engage in any form of general
solicitation or general advertising in connection with the offering of the Notes
(as those terms are used in Regulation D) under the Securities Act or in any
manner involving a public offering within the meaning of Section 4(2) of the
Securities Act; the Company has not entered into any contractual arrangement
with respect to the distribution of the Notes except for this Agreement and the
Company will not enter into any such arrangement.

         (kk) None of the Company or any of its affiliates (other than the
Initial Purchasers, about which no representation is made by the Company), has,
directly or through any agent, sold, offered for sale, solicited offers to buy
or otherwise negotiated in respect of, any "security" (as defined in the
Securities Act) which is or will be integrated with the sale of the Notes in a
manner that would require the registration under the Securities Act of the
Notes.

         (ll) The Company has not taken, directly or indirectly, any action
designed to cause or result in, or which has constituted or which might
reasonably be expected to constitute, the stabilization or manipulation of the
price of any security of the Company in connection with the offering of the
Notes.

2. PURCHASE, SALE AND DELIVERY OF NOTES.

         (a) Subject to the terms and conditions and in reliance upon the
representations and warranties herein set forth, the Company agrees to sell to
each Initial Purchaser, and each Initial Purchaser agrees, severally and not
jointly, to purchase from the Company, at a purchase price of 96.875% of the
principal amount thereof (the "purchase price") the principal amount of Firm
Notes set forth opposite such Initial Purchaser's name in SCHEDULE I hereto (or
such number increased as set forth in Section 8).

         Delivery of and payment for the Firm Notes shall be made at the office
of Brown & Wood LLP, One World Trade Center, New York, New York 10048, at 10:00
a.m. (New York City time) on February 8, 2000, or such later date as the Initial
Purchasers shall designate, which date and time may be postponed by agreement
between the Initial Purchasers and the Company or as provided in Section 8 (such
date and time of delivery and payment for the Firm Notes being herein called the
"First Delivery Date"). Delivery of the Firm Notes shall be made to the Initial
Purchasers against payment of the purchase price by the Initial Purchasers.
Payment for the Firm Notes shall be effected either by wire transfer of
immediately available funds to an account with a bank in The City of New York,
the account number and the ABA number for such bank to be provided by the
Company to the Initial Purchasers at least two business days in advance of the
First Delivery Date, or by such other manner of payment as may be agreed by the
Company and the Initial Purchasers. It is understood that each Initial Purchaser
has authorized the Representatives, for its account, to accept delivery of,
issue a receipt for, and make payment of the purchase price for, the Firm Notes
that it has agreed to purchase. Merrill Lynch, individually

                                       11
<PAGE>

and not as representative of the Initial Purchasers, may (but shall not be
obligated to) make payment of the purchase price for the Firm Notes to be
purchased by any Initial Purchaser whose funds have not been received by the
First Delivery Date but such payment shall not relieve such Initial Purchaser
from its obligations hereunder.

         (b) Subject to the terms and conditions and in reliance upon the
representations and warranties herein set forth, the Company hereby grants the
Option to the Initial Purchasers to purchase, severally and not jointly, the
Optional Notes at the same price as the Initial Purchasers shall pay for the
Firm Notes and the principal amount of the Optional Notes to be sold to each
Initial Purchaser shall be that principal amount which bears the same ratio to
the aggregate principal amount of Optional Notes being purchased as the
principal amount of Firm Notes set forth opposite the name of such Initial
Purchaser in SCHEDULE I hereto (or such number increased as set forth in Section
8). The Option may be exercised only to cover over-allotments in the sale of the
Firm Notes by the Initial Purchasers. The Option may be exercised once in whole
or in part at any time not more than 30 days subsequent to the date of this
Agreement upon notice in writing or by facsimile by the Representatives to the
Company setting forth the amount (which shall be an integral multiple of $1,000)
of Optional Notes as to which the Initial Purchasers are exercising the Option.

         The date for the delivery of and payment for the Optional Notes, being
herein referred to as an "Optional Delivery Date", which may be the First
Delivery Date (the First Delivery Date and the Optional Delivery Date, if any,
being sometimes referred to as a "Delivery Date"), shall be determined by the
Initial Purchasers but shall not be later than five full business days after
written notice of election to purchase Optional Notes is given. Delivery of the
Optional Notes shall be made to the Initial Purchasers against payment of the
purchase price by the Initial Purchasers. Payment for the Optional Notes shall
be effected either by wire transfer of immediately available funds to an account
with a bank in The City of New York, the account number and the ABA number for
such bank to be provided by the Company to the Initial Purchasers at least two
business days in advance of the Optional Delivery Date, or by such other manner
of payment as may be agreed by the Company and the Initial Purchasers. It is
understood that each Initial Purchaser has authorized the Representatives, for
its account, to accept delivery of, issue a receipt for, and make payment of the
purchase price for, the Optional Notes that it has agreed to purchase. Merrill
Lynch, individually and not as representative of the Initial Purchasers, may
(but shall not be obligated to) make payment of the purchase price for the
Optional Notes to be purchased by any Initial Purchaser whose funds have not
been received by the Delivery Date but such payment shall not relieve such
Initial Purchaser from its obligations hereunder.

         (c) The Company will deliver against payment of the purchase price the
Notes initially sold to qualified institutional buyers ("QIBs"), as defined in
Rule 144A under the Securities Act ("Rule 144A") in the form of one or more
permanent global certificates (the "Global Notes"), registered in the name of
Cede & Co., as nominee for The Depository Trust Company ("DTC"). Beneficial
interests in the Notes initially sold to QIBs will be shown on, and transfers
thereof will be effected only through, records maintained in book-entry form by
DTC and its participants.

                                       12
<PAGE>

         The Global Notes will be made available, at the request of the Initial
Purchasers, for checking at least 24 hours prior to such Delivery Date. The
Certificated Notes will be made available, at the request of the Initial
Purchasers, for checking at least 48 hours prior to such Delivery Date.

         (d) Time shall be of the essence, and delivery at the time and place
specified pursuant to this Agreement is a further condition of the obligations
of the Initial Purchasers hereunder.

3. FURTHER AGREEMENTS OF THE COMPANY. The Company further agrees with each
Initial Purchaser as follows:

         (a) The Company will advise the Initial Purchasers promptly of any
proposal to amend or supplement the Offering Memorandum and not to effect any
such amendment or supplement without the consent of the Initial Purchasers
and/or Brown & Wood LLP, counsel to the Initial Purchasers. Neither the consent
of the Initial Purchasers, nor the Initial Purchaser's delivery of any such
amendment or supplement, shall constitute a waiver of any of the conditions set
forth in Section 5. The Company will immediately notify each Initial Purchaser,
and confirm such notice in writing, of (i) any filing made by the Company of
information relating to the offering of the Notes by the Company with any
securities exchange or any other regulatory body in the United States or any
other jurisdiction, and (ii) prior to the completion of the placement of the
Notes by the Initial Purchasers as evidenced by a notice in writing from the
Initial Purchasers to the Company, any material changes in or affecting the
condition, financial or otherwise, or the earnings, business affairs or business
prospects of the Company which (x) make any statement in the Offering Memorandum
false or misleading or (y) are not disclosed in the Offering Memorandum. In such
event or if during such time any event shall occur or condition exist as a
result of which it is necessary to amend or supplement the Offering Memorandum
in order that the Offering Memorandum will not include an untrue statement of a
material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances existing at the time it is
delivered to a purchaser, not misleading, to promptly notify the Initial
Purchasers and/or Brown & Wood LLP, counsel to the Initial Purchasers, and
prepare, subject to the first sentence of this Section 3(a), such amendment or
supplement as may be necessary to correct such untrue statement or omission.

         (b) The Company will furnish to the Initial Purchasers and to Brown &
Wood LLP, counsel to the Initial Purchasers, copies of the Preliminary Offering
Memorandum and the Offering Memorandum (and all amendments and supplements
thereto) in each case as soon as available and in such quantities as the Initial
Purchasers reasonably request for internal use and for distribution to
prospective purchasers; and to furnish to the Initial Purchasers on the date
hereof four copies of the Offering Memorandum signed by duly authorized officers
of the Company, one of which will include the independent auditors' reports
therein manually signed by such independent auditors. The Company will pay the
expenses of printing and distributing to the Initial Purchasers all such
documents.

         (c) The Company will use its reasonable efforts to take such action as
the Initial Purchasers may reasonably request from time to time, to qualify the
Notes and the Conversion

                                       13
<PAGE>

Shares for offering and sale under the securities laws of such jurisdictions as
the Initial Purchasers may request and to comply with such laws so as to permit
the continuance of sales and dealings therein in such jurisdictions in the
United States for as long as may be necessary to complete the resale of the
Notes; PROVIDED that in connection therewith, the Company shall not be required
to qualify as a foreign corporation or otherwise subject itself to taxation in
any jurisdiction in which it is not otherwise so qualified or subject.

         (d) The Company will apply the proceeds from the sale of the Notes as
set forth under "Use of Proceeds" in the Offering Memorandum.

         (e) During a period of 90 days from the date of the Offering
Memorandum, the Company will not, and will cause its directors and officers not
to, without the prior written consent of Merrill Lynch, (i) directly or
indirectly, offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option right or
warrant to purchase or otherwise transfer or dispose of any Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock
(collectively, the "Restricted Securities") or file any registration statement
under the Securities Act with respect to any Restricted Securities, or (ii)
enter into any swap or any other agreement or any transaction (other than the
Operative Documents) that transfers, in whole or in part, directly or
indirectly, the economic consequence of ownership of any Restricted Securities,
whether any such swap or transaction described in clause (i) or (ii) above is to
be settled by delivery of Restricted Securities, in cash or otherwise. The
foregoing sentence shall not apply to Authorized Grants, the Old Conversion
Shares, the Conversion Shares or the sale of up to $125 million in the aggregate
of the Company's Common Stock (as measured on the date of such sales(s)) only
(x) in a private placement or (y) in connection with the Company's acquisition
of a company not subject to the reporting requirements of the Exchange Act. The
Company further agrees not to permit to become effective under the Securities
Act during a period of 90 days from the date of the Offering Memorandum a
registration statement covering any shares of the Company's Common Stock sold
pursuant to a transaction described in clauses (x) and (y) above. The Company
further agrees to cause each officer and director of the Company to furnish to
the Initial Purchasers, prior to the First Delivery Date, a letter or letters,
in form and substance satisfactory to counsel to the Initial Purchasers,
pursuant to which each such person shall agree not to enter into any transaction
described in clause (i) or (ii) of the first sentence of this paragraph;
PROVIDED, HOWEVER, that such restrictions shall not apply to the sale of up to
400,000 shares of Common Stock in the aggregate by all such officers and
directors.

         (f) The Company agrees that it will not, and will cause its Affiliates
(as defined in Rule 501(b) of Regulation D) not to, directly or indirectly,
solicit any offer to buy, sell or make any offer or sale of, or otherwise
negotiate in respect of, securities of the Company of any class if, as a result
of the doctrine of "integration" referred to in Rule 502 under the Securities
Act, such offer or sale would render invalid (for the purpose of (i) the sale of
the Notes by the Company to the Initial Purchasers, (ii) the resale of the Notes
by the Initial Purchasers to subsequent purchasers or (iii) the resale of the
Notes or Conversion Shares by such subsequent purchasers to others) the
exemption from the registration requirements of the Securities Act provided by
Section 4(2) thereof or by Rule 144A thereunder or otherwise. Notwithstanding
the

                                       14
<PAGE>

foregoing, no stockholder of the Company that does not control, is not
controlled by or is not under common control with, an officer or director of the
Company shall be deemed to be an Affiliate for purposes of this paragraph.

         (g) For so long as any of the Notes are "restricted securities" within
the meaning of Rule 144(a)(3) under the Securities Act, the Company will provide
to any holder of the Notes or to any prospective purchaser of the Notes
designated by any holder, upon request of such holder or prospective purchaser,
information required to be provided by Rule 144A(d)(4) of the Securities Act if,
at the time of such request, the Company is not subject to the reporting
requirements under Section 13 or 15(d) of the Exchange Act.

         (h) Until the expiration of two years after the original issuance of
the Notes, the Company will not, and will cause its Affiliates (as defined in
Rule 501(b) of Regulation D) not to, resell any Notes or Conversion Shares which
are "restricted securities" (as such term is defined under Rule 144(a)(3) under
the Securities Act), whether as beneficial owner or otherwise (except as agent
acting as a securities broker on behalf of and for the account of customers in
the ordinary course of business in unsolicited broker's transactions).
Notwithstanding the foregoing, no stockholder of the Company that does not
control, is not controlled by or is not under common control with, an officer or
director of the Company shall be deemed to be an Affiliate for purposes of this
paragraph.

         (i) Each of the Notes will bear, to the extent applicable, the legend
contained in "Notice to Investors" in the Offering Memorandum for the time
period and upon the other terms stated therein, except after the Notes are
resold pursuant to a registration statement effective under the Securities Act.

         (j) The Company will take such steps as shall be necessary to ensure
that it shall not become an "investment company" within the meaning of such term
under the Investment Company Act, and the rules and regulations of the
Commission thereunder.

         (k) None of the Company or any of its affiliates will take, directly or
indirectly, any action which is designed to stabilize or manipulate, or which
constitutes or which might reasonably be expected to cause or result in
stabilization or manipulation, of the price of any security of the Company in
connection with the offering of the Notes.

         (l) The Company will execute and deliver the Registration Rights
Agreement in form and substance satisfactory to the Initial Purchasers.

         (m) The Company will use its best efforts to assist the Initial
Purchasers in arranging to cause the Notes to be accepted to trade in the PORTAL
market ("PORTAL") of the National Association of Securities Dealers, Inc.
("NASD").

         (n) The Company will use its best efforts to cause the Notes to be
accepted for clearance and settlement through the facilities of DTC.

                                       15
<PAGE>

         (o) The Company will use its best efforts to have the Conversion Shares
approved by the Nasdaq National Market ("Nasdaq") for inclusion prior to the
effectiveness of the Registration Statement.

         (p) The Company has not taken, and prior to March 1, 2000 shall not
take, directly or indirectly, any action which releases Baxter from or waives
any restriction imposed on Baxter with respect to the transfer of shares of
Common Stock contained in the Stock Purchase Agreement between Baxter and the
Company, dated March 1, 1996, as amended.

4. EXPENSES. The Company agrees to pay:

         (a) the costs incident to the authorization, issuance, sale and
delivery of the Notes, and any taxes payable in that connection;

         (b) the costs incident to the preparation, printing and distribution of
the Preliminary Offering Memorandum, the Offering Memorandum and any amendment
or supplement to the Offering Memorandum, all as provided in this Agreement;

         (c)  the costs of producing and distributing the Operative Documents;

         (d) the fees and expenses of Cooley Godward LLP and Ernst & Young LLP;

         (e) the costs of distributing the terms of agreement relating to the
organization of the underwriting syndicate and selling group to the members
thereof by mail, telex or other means of communication;

         (f) the fees and expenses of qualifying the Notes under the securities
laws of the several jurisdictions as provided in Section 3(c);

         (g) all costs and expenses incident to (i) the preparation of the "road
show" presentation materials and (ii) the road show travelling expenses of the
Company;

         (h)  the costs of preparing the Notes;

         (i) all expenses and fees in connection with the application for
inclusion of the Notes in the PORTAL market and the inclusion of the Conversion
Shares on the NASDAQ;

         (j) the fees and expenses (including fees and disbursements of counsel)
of the Trustee, and the costs and charges of any registrar, transfer agent,
paying agent or conversion agent; and

         (k) all other costs and expenses incident to the performance of the
obligations of the Company under this Agreement;

PROVIDED that, except as provided in this Section 4 and in Section 7, the
Initial Purchasers shall pay their own costs and expenses, including the costs
and expenses of their counsel and any transfer taxes on the Notes which they may
sell.

                                       16
<PAGE>

5. CONDITIONS OF THE INITIAL PURCHASERS' OBLIGATIONS. The several obligations of
the Initial Purchasers hereunder are subject to the accuracy, when made and on
each Delivery Date, of the representations and warranties of the Company
contained herein, to the performance by the Company of its obligations
hereunder, and to each of the following additional terms and conditions:

         (a) No Initial Purchaser shall have discovered and disclosed to the
Company prior to or on such Delivery Date that the Offering Memorandum or any
amendment or supplement thereto contains any untrue statement of a fact which,
in the opinion of counsel to the Initial Purchasers, is material or omits to
state any fact which is material and necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading.

         (b) All corporate proceedings and other legal matters incident to the
authorization, form and validity of the Operative Documents and the Offering
Memorandum or any amendment or supplement thereto, and all other legal matters
relating to the Operative Documents and the transactions contemplated thereby
shall be satisfactory in all material respects to counsel to the Initial
Purchasers, and the Company shall have furnished to such counsel all documents
and information that they may reasonably request to enable them to pass upon
such matters.

         (c) Cooley Godward LLP shall have furnished to the Initial Purchasers
their written opinion, as counsel to the Company, addressed to the Initial
Purchasers and dated such Delivery Date, in form and substance satisfactory to
the Initial Purchasers, to the effect that:

                  (i) The Company has been duly organized and is validly
existing as a corporation in good standing under the laws of the State of
Delaware, and, based solely on certificates of public officials, is duly
qualified to do business and is in good standing as a foreign corporation in
each jurisdiction in which its ownership or lease of property or the conduct of
its business requires such qualification, except where the failure to be so
qualified would not have a material adverse effect on the Company, whether or
not arising in the ordinary course of business, and has all corporate power and
authority necessary to own or hold its properties and conduct the businesses in
which it is engaged, as described in the Offering Memorandum; and, to the
knowledge of such counsel, the Company has no subsidiaries;

                  (ii) the Conversion Shares, which are authorized on the date
        hereof, have been duly and validly authorized and reserved for issuance
        upon conversion of the Notes by all necessary corporate action and are
        free of preemptive rights; all Conversion Shares, when so issued and
        delivered upon such conversion in accordance with the terms of the
        Indenture, will be duly and validly authorized and issued, fully paid
        and nonassessable and free and clear of all liens, encumbrances,
        equities or claims imposed by or arising from actions of the Company;

                  (iii) The statements in the Offering Memorandum under the
captions "Description of the Notes" and "Description of Capital Stock", insofar
as they purport to summarize the provisions of the Indenture, the Registration
Rights Agreement, the Notes and the Common Stock (including the Conversion
Shares) are accurate and complete in all material

                                       17
<PAGE>

respects to the extent required if such statements were contained in a
registration statement on Form S-3 under the Securities Act;

                  (iv) There is no restriction upon the voting or transfer of,
any shares of Common Stock pursuant to the Company's certificate of
incorporation or bylaws;

                  (v) To the knowledge of such counsel and other than as set
forth in the Offering Memorandum, there are no legal or governmental proceedings
pending to which the Company is a party or of which any property or asset of the
Company is the subject which, if determined adversely to the Company might have
a material adverse effect on the Company or which might reasonably be expected
to materially and adversely affect the consummation of the transactions
contemplated by this Agreement or the performance by the Company of its
obligations hereunder; to the actual knowledge of such counsel, no such
proceedings are overtly threatened or contemplated by governmental authorities
or, except as set forth or contemplated in the Offering Memorandum, overtly
threatened by others; and, to the actual knowledge of such counsel, the
aggregate of all pending legal or governmental proceedings to which the Company
is a party or of which any of its property or assets is the subject (other than
the Company's patent applications currently pending before the U.S. Patent and
Trademark Office or before any foreign governmental authority that administers
the registration of patents) which are not described in the Offering Memorandum,
including ordinary routine litigation incidental to the business, could not
reasonably be expected to result in a material adverse effect on the Company.

                  (vi) The execution, delivery and performance of this
Agreement, the Indenture and the Registration Rights Agreement and the issuance
of the Notes and the Conversion Shares and the consummation of the transactions
contemplated hereby and thereby do not result in any violation of the provisions
of the certificate of incorporation or bylaws of the Company or any statute or
any order, rule or regulation known to such counsel of any court or governmental
agency or body having jurisdiction over the Company or any of its properties or
assets; and, except as may be required by the securities or "blue sky" laws of
any state of the United States in connection with the sale of the Notes, no
consent, approval, authorization or order of, or filing or registration with,
any such court or governmental agency or body is required for the execution,
delivery and performance of this Agreement and the Indenture by the Company and
the issuance of the Notes and the Conversion Shares and the consummation of the
transactions contemplated hereby and thereby;

                  (vii) No registration of the Notes or the Conversion Shares
under the Securities Act, and no qualification of the Indenture or an indenture
under the Trust Indenture Act, is required in connection with the offer, sale
and delivery of the Notes or in connection with the conversion of the Notes into
Conversion Shares, in each case, in the manner contemplated by the Offering
Memorandum, this Agreement and the Indenture;

                  (viii) The statements in the Offering Memorandum under the
caption "Certain United States Federal Income Tax Considerations", insofar as
they purport to constitute summaries of matters of United States federal income
tax law and regulations or legal conclusions with respect thereto, constitute
accurate summaries of the matters described therein

                                       18
<PAGE>

in all material respects to the extent required if such statements were
contained in a registration statement on Form S-3 under the Securities Act;

                  (ix) The Company is not an "investment company" within the
meaning of the Investment Company Act of 1940, as amended;

                  (x) The Company has all necessary corporate right, power and
authority to execute and deliver each of the Operative Documents to which it is
a party and to perform its obligations thereunder and to issue, sell and deliver
the Notes and the Conversion Shares to the Initial Purchasers;

                  (xi) This Agreement has been duly authorized, executed and
delivered by the Company;

                  (xii) The Indenture has been duly authorized, executed and
delivered by the Company and, assuming due authorization, execution and delivery
thereof by the Trustee, constitutes a legally valid and binding agreement of the
Company enforceable against the Company in accordance with its terms except as
the enforceability thereof may be limited by bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and other similar laws relating to or
affecting creditors' rights generally, subject to general principles of equity
and to limitations on availability of equitable relief, including specific
performance (regardless of whether such enforceability is considered in a
proceeding in equity or at law) or by an implied covenant of good faith and fair
dealing;

                  (xiii) The Registration Rights Agreement has been duly
authorized, executed and delivered by the Company and, assuming due
authorization, execution and delivery thereof by the Initial Purchasers,
constitutes a valid and legally binding agreement of the Company enforceable
against the Company in accordance with its terms except as rights to indemnity
contained therein may be limited by applicable law and except as the
enforceability thereof may be limited by bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and other similar laws relating to or
affecting creditors' rights generally, subject to general principles of equity
and to limitations on availability of equitable relief, including specific
performance (regardless of whether such enforceability is considered in a
proceeding in equity or at law), by an implied covenant of good faith and fair
dealing; and

                  (xiv) The Notes have been duly authorized by the Company and
when executed, issued and authenticated in accordance with terms of the
Indenture and delivered to and paid for by the Initial Purchasers, will
constitute legally valid and binding obligations of the Company, entitled to the
benefits of the Indenture and enforceable against the Company in accordance with
their terms except as the enforceability thereof may be limited by bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and other similar
laws relating to or affecting creditors' rights generally, subject to general
principles of equity and to limitations on availability of equitable relief,
including specific performance (regardless of whether such enforceability is
considered in a proceeding in equity or at law) or by an implied covenant of
good faith and fair dealing.

                                       19
<PAGE>

         In rendering such opinion, such counsel may state that its opinion is
limited to matters governed by the federal laws of the United States of America,
the laws of the State of New York and the Delaware General Corporation Law and
may state that it is relying, in respect of matters of New York law, upon Brown
& Wood LLP, and in respect of matters of fact, upon certificates of officers of
the Company, PROVIDED that such counsel shall state that it believes that the
Initial Purchasers and it are justified in relying upon such certificates. Such
counsel shall also have furnished to the Initial Purchasers a written statement,
addressed to the Initial Purchasers and dated such Delivery Date, in form and
substance satisfactory to the Initial Purchasers, to the effect that during the
course of preparing the Offering Memorandum, such counsel participated in
conferences with officers and other representatives of the Company, the
Company's independent public accountants, the Initial Purchasers and their
counsel, at which the contents of the Offering Memorandum were discussed, and
while such counsel has not independently verified and is not passing upon the
accuracy, completeness or fairness of the statements made in the Offering
Memorandum except as explicitly set forth above, no facts have come to the
attention of such counsel which lead it to believe that the Offering Memorandum
(other than the financial statements, financial and statistical data and
supporting schedules as to which such counsel shall make no statement), as of
its date or as of such Delivery Date, contained or contains any untrue statement
of a material fact or omitted or omits to state a material fact necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading.

         (d) Stephen L. Hurst, Esq., General Counsel and Secretary of the
Company, shall have furnished to the Initial Purchasers his written opinion,
addressed to the Initial Purchasers and dated such Delivery Date, in form and
substance satisfactory to the Initial Purchasers, to the effect that:

                  (i) The authorized, issued and outstanding capital stock of
the Company, as of September 30, 1999, is as set forth in the Offering
Memorandum under the column entitled "Actual" under the caption
"Capitalization", and all of the issued and outstanding shares of capital stock
of the Company have been duly and validly authorized and issued, are fully paid
and nonassessable;

                  (ii) Except as disclosed in the Offering Memorandum, there are
no preemptive or other rights to subscribe for or to purchase from the Company,
or any restriction upon the voting or transfer of, any shares of Common Stock
pursuant to any agreement or other instrument to which the Company is a party
known to such counsel; the issuance of the Conversion Shares, upon conversion of
the Notes in accordance with the terms of the Indenture, will not be subject to
the preemptive or other similar rights of any securityholder of the Company and

                  (iii) The execution, delivery and performance of this
Agreement, the Indenture and the Registration Rights Agreement and the issuance
of the Notes and the Conversion Shares and the consummation of the transactions
contemplated hereby and thereby do not result in a breach or violation of any of
the terms or provisions of, or constitute a default under, any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument known
to

                                       20
<PAGE>

such counsel to which the Company is a party or by which the Company is bound or
to which any of the property or assets of the Company is subject.

         Such counsel shall also have furnished to the Initial Purchasers a
written statement, addressed to the Initial Purchasers and dated such Delivery
Date, in form and substance satisfactory to the Initial Purchasers, to the
effect that he has no reason to believe that the statements under the captions
"Risk Factors--Our patents may not protect our products and our products may
infringe on third-party patent rights" and "Patents and Proprietary Rights" in
the Offering Memorandum, as of its date or as of such Delivery Date, contained
or contains any untrue statement of a material fact or omitted or omits to state
a material fact necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading.

         (e) Brown & Wood LLP, shall have furnished to the Initial Purchasers
their written opinion, as counsel to the Initial Purchasers, addressed to the
Initial Purchasers and dated such Delivery Date, in form and substance
satisfactory to the Initial Purchasers.

         (f) With respect to the letter of Ernst & Young LLP delivered to the
Initial Purchasers concurrently with the execution of this Agreement (the
"initial letter"), the Company shall have furnished to the Initial Purchasers a
letter (the "bring-down letter") of such accountants, addressed to the Initial
Purchasers and dated such Delivery Date (i) confirming that they are independent
accountants within the meaning of the Securities Act and are in compliance with
the applicable requirements relating to the qualification of accountants under
Rule 2-01 of Regulation S-X of the Commission, (ii) stating, as of the date of
the bring-down letter (or, with respect to matters involving changes or
developments since the respective dates as of which specified financial
information is given in the Offering Memorandum, as of a date not more than five
days prior to the date of the bring-down letter), the conclusions and findings
of such firm with respect to the financial information and other matters covered
by the initial letter and (iii) confirming in all material respects the
conclusions and findings set forth in the initial letter.

         (g) The Company shall have furnished to the Initial Purchasers on such
Delivery Date a certificate, dated such Delivery Date and delivered on behalf of
the Company by one of its co-chief executive officers and its chief financial
officer, in form and substance satisfactory to the Initial Purchasers, to the
effect that:

                  (i) The representations, warranties and agreements of the
Company in Section 1 are true and correct as of the date given and as of such
Delivery Date; and the Company has complied in all material respects with all
its agreements contained herein to be performed prior to or on such Delivery
Date;

                  (ii) (A) The Company has not sustained since the date of the
latest audited financial statements included in the Offering Memorandum any loss
or interference with its business from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, except (x) as set forth or contemplated in
the Offering Memorandum and (y) for operating losses incurred in the ordinary
course of business, or (B) since such date there has not been any change in the
capital stock or

                                       21
<PAGE>

long-term debt of the Company (except for issuances of shares of Common Stock
upon exercise of outstanding options described in the Offering Memorandum or
pursuant to Authorized Grants), or any change, or any development involving a
prospective change, in or affecting the general affairs, management, financial
position, stockholders' equity or results of operations of the Company, except
as set forth or contemplated in the Offering Memorandum; and

                  (iii) Such officer has carefully examined the Offering
Memorandum and, in such officer's opinion (A) the Offering Memorandum, as of its
date, did not include any untrue statement of a material fact and did not omit
to state any material fact necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading, and (B)
since the date of the Offering Memorandum, no event has occurred which should
have been set forth in a supplement or amendment to the Offering Memorandum.

         (h) The Indenture shall have been duly executed and delivered by the
Company and the Trustee and the Notes shall have been duly executed and
delivered by the Company and duly authenticated by the Trustee.

         (i) The Company and the Initial Purchasers shall have executed and
delivered the Registration Rights Agreement (in form and substance satisfactory
to the Initial Purchasers) and the Registration Rights Agreement shall be in
full force and effect.

         (j) The NASD shall have accepted the Notes for trading on PORTAL.

         (k) (i) The Company shall not have sustained since the date of the
latest audited financial statements included in the Offering Memorandum any loss
or interference with its business from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, except (A) as set forth or contemplated in
the Offering Memorandum and (B) for operating losses incurred in the ordinary
course of business, or (ii) since such date there shall not have been any change
in the capital stock or long-term debt of the Company (except for issuances of
shares of Common Stock upon exercise of outstanding options described in the
Offering Memorandum or pursuant to Authorized Grants), or any change, or any
development involving a prospective change, in or affecting the general affairs,
management, financial position, stockholders' equity or results of operations of
the Company, except as set forth or contemplated in the Offering Memorandum, the
effect of which, in any such case described in clause (i) or (ii), is, in the
reasonable judgment of the Initial Purchasers, so material and adverse as to
make it impracticable or inadvisable to proceed with the sale or the delivery of
the Notes being delivered on such Delivery Date on the terms and in the manner
contemplated in the Offering Memorandum.

         (l) The Company shall have furnished to the Initial Purchasers such
further information, certificates and documents as the Initial Purchasers may
reasonably request to evidence compliance with the conditions set forth in this
Section 5.

         All opinions, letters, evidence and certificates mentioned above or
elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance satisfactory to counsel
to the Initial Purchasers.

                                       22
<PAGE>

         If any condition specified in this Section 5 shall not have been
fulfilled when and as required to be fulfilled, this Agreement may be terminated
by the Representatives by notice to the Company at any time at or prior to the
First Delivery Date, and such termination shall be without liability of any
party to any other party except as provided in Section 4 and except that
Sections 1 and 7 shall survive any such termination and remain in full force and
effect.

6. REPRESENTATIONS, WARRANTIES AND AGREEMENTS OF INITIAL PURCHASERS. Each
Initial Purchaser, severally and not jointly, represents and warrants that such
Initial Purchaser is a QIB. Each Initial Purchaser, severally and not jointly,
agrees with the Company that:

         (a) The Notes and the Conversion Shares have not been and will not be
registered under the Securities Act in connection with the initial offering of
the Notes.

         (b)  Such Initial Purchaser is a QIB;

         (c) Such Initial Purchaser will not offer or sell the Notes in the
United States by means of any form of general solicitation or general
advertising within the meaning of Rule 502(c) of Regulation D, including (i) any
advertisement, article, notice or other communication published in any
newspaper, magazine or similar medium or broadcast over television or radio, or
(ii) any seminar or meeting whose attendees have been invited by any general
solicitation or general advertising in the United States; and

         (d) Such Initial Purchaser has not offered or sold, and will not offer
or sell, any Notes in the United States except to persons whom it reasonably
believes to be QIBs.

7.   INDEMNIFICATION AND CONTRIBUTION.

         (a) The Company shall indemnify and hold harmless each Initial
Purchaser, its officers and employees and each person, if any, who controls any
Initial Purchaser within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act from and against any loss, claim, damage or
liability, joint or several, or any action in respect thereof (including, but
not limited to, any loss, claim, damage, liability or action relating to
purchases and sales of the Notes), to which that Initial Purchaser, officer,
employee or controlling person may become subject:

                  (i) insofar as such loss, claim, damage, liability or action
arises out of, or is based upon: (A) any untrue statement or alleged untrue
statement of a material fact contained in (I) any Preliminary Offering
Memorandum or the Offering Memorandum, or in any amendment or supplement
thereto, or (II) any blue sky application or other document prepared or executed
by the Company (or based upon any written information furnished by the Company)
filed in any jurisdiction specifically for the purpose of qualifying any or all
of the Notes under the securities laws of any state or other jurisdiction (such
application, document or information being hereinafter called a "Blue Sky
Application"), or (B) the omission or alleged omission to state therein any
material fact necessary to make the statements therein not misleading; or

                                       23
<PAGE>

                  (ii) to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any governmental agency
or body, commenced or threatened, or of any claim whatsoever based upon any such
untrue statement or omission, or any such alleged untrue statement or omission;
provided that (subject to Section 7(c)) any such settlement is effected with the
written consent of the Company,

and shall reimburse each Initial Purchaser and each such officer, employee and
controlling person promptly upon demand for any and all expense whatsoever, as
incurred (including the fees and disbursements of counsel chosen by Merrill
Lynch, except as reimbursement of such fees may be limited by Section 7(c)),
reasonably incurred by that Initial Purchaser, officer, employee or controlling
person in connection with investigating or defending or preparing to defend
against any such loss, claim, damage, liability or action as such expenses are
incurred; PROVIDED, HOWEVER, that the Company shall not be liable in any such
case to the extent that any such loss, claim, damage, liability or action arises
out of, or is based upon, any untrue statement or alleged untrue statement or
omission or alleged omission made in any Preliminary Offering Memorandum or the
Offering Memorandum, or in any such amendment or supplement, or in any Blue Sky
Application in reliance upon and in conformity with the written information
furnished to the Company by or on behalf of any Initial Purchaser specifically
for inclusion therein and described in Section 7(e); PROVIDED, FURTHER, that as
to any Preliminary Offering Memorandum, this indemnity agreement shall not inure
to the benefit of any Initial Purchaser, its officers or employees or any person
controlling that Initial Purchaser on account of any loss, claim, damage,
liability or action arising from the sale of Notes to any person by that Initial
Purchaser if that Initial Purchaser failed to send or give a copy of the
Offering Memorandum, as the same may be amended or supplemented, to that person,
and the untrue statement or alleged untrue statement of a material fact or
omission or alleged omission to state a material fact in such Preliminary
Offering Memorandum was corrected in the Offering Memorandum, unless such
failure resulted from non-compliance by the Company with Section 3(b). The
foregoing indemnity agreement is in addition to any liability which the Company
may otherwise have to any Initial Purchaser or to any officer, employee or
controlling person of that Initial Purchaser.

         (b) Each Initial Purchaser, severally and not jointly, shall indemnify
and hold harmless, the Company, its officers and directors, and each person, if
any, who controls the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act from and against any loss, claim, damage
or liability, joint or several, or any action in respect thereof, to which the
Company or any such director, officer or controlling person may become subject,
insofar as such loss, claim, damage, liability or action arises out of, or is
based upon:

                  (i) any untrue statement or alleged untrue statement of a
material fact contained in any Preliminary Offering Memorandum or the Offering
Memorandum or in any amendment or supplement thereto, or in any Blue Sky
Application, or

                  (ii) the omission or alleged omission to state therein any
material fact necessary to make the statements therein not misleading,

                                       24
<PAGE>

but in each case only to the extent that such untrue statement or alleged untrue
statement or omission or alleged omission was made in reliance upon and in
conformity with the written information furnished to the Company by or on behalf
of that Initial Purchaser specifically for inclusion therein and described in
Section 7(e), and shall reimburse the Company and any such director, officer or
controlling person promptly upon demand for any legal or other expenses
reasonably incurred by the Company or any such director, officer or controlling
person in connection with investigating or defending or preparing to defend
against any such loss, claim, damage, liability or action as such expenses are
incurred. The foregoing indemnity agreement is in addition to any liability
which any Initial Purchaser may otherwise have to the Company or any such
director, officer or controlling person.

         (c) Promptly after receipt by an indemnified party under this Section 7
of notice of any claim or the commencement of any action, the indemnified party
shall, if a claim in respect thereof is to be made against the indemnifying
party under this Section 7, notify the indemnifying party in writing of the
claim or the commencement of that action; PROVIDED, HOWEVER, that the failure to
notify the indemnifying party shall not relieve it from any liability which it
may have under this Section 7 except to the extent it has been materially
prejudiced by such failure and, PROVIDED, FURTHER, that the failure to notify
the indemnifying party shall not relieve it from any liability which it may have
to an indemnified party otherwise than under this Section 7. If any such claim
or action shall be brought against an indemnified party, and it shall notify the
indemnifying party thereof, the indemnifying party shall be entitled to
participate therein and, to the extent that it wishes, jointly with any other
similarly notified indemnifying party, to assume the defense thereof with
counsel satisfactory to the indemnified party. After notice from the
indemnifying party to the indemnified party of its election to assume the
defense of such claim or action, the indemnifying party shall not be liable to
the indemnified party under this Section 7 for any legal or other expenses
subsequently incurred by the indemnified party in connection with the defense
thereof other than reasonable costs of investigation; PROVIDED, HOWEVER, that
the Initial Purchasers shall have the right to employ counsel to represent
jointly the Initial Purchasers and their respective officers, employees and
controlling persons who may be subject to liability arising out of any claim in
respect of which indemnity may be sought by the Initial Purchasers against the
Company under this Section 8, if the Initial Purchasers shall have reasonably
concluded that there may be one or more legal defenses available to the Initial
Purchasers and their respective officers, employees and controlling persons that
are different from or additional to those available to the Company and its
officers, employees and controlling persons, the fees and expenses of a single
separate counsel shall be paid by the Company. No indemnifying party shall:

                  (i) without the prior written consent of the indemnified
        parties (which consent shall not be unreasonably withheld) settle or
        compromise or consent to the entry of any judgment with respect to any
        pending or threatened claim, action, suit or proceeding in respect of
        which indemnification or contribution may be sought hereunder (whether
        or not the indemnified parties are actual or potential parties to such
        claim or action) unless such settlement, compromise or consent includes
        an unconditional release of each indemnified party from all liability
        arising out of such claim, action, suit or proceeding, or

                                       25
<PAGE>

                  (ii) be liable for any settlement of any such action effected
        without its written consent (which consent shall not be unreasonably
        withheld), but if settled with its written consent or if there be a
        final judgment of the plaintiff in any such action, the indemnifying
        party agrees to indemnify and hold harmless any indemnified party from
        and against any loss of liability by reason of such settlement or
        judgment.

         (d) If the indemnification provided for in this Section 7 shall for any
reason be unavailable or insufficient to hold harmless an indemnified party
under Section 7(a) or 7(b) in respect of any loss, claim, damage or liability,
or any action in respect thereof, referred to therein, each indemnifying party
shall, in lieu of indemnifying such indemnified party, contribute to the amount
paid or payable by such indemnified party as a result of such loss, claim,
damage or liability, or action in respect thereof:

                  (i) in such proportion as shall be appropriate to reflect the
relative benefits received by the Company on the one hand and the Initial
Purchasers on the other from the offering of the Notes, or

                  (ii) if the allocation provided by clause 7(d)(i) is not
permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause 7(d)(i) but also the relative
fault of the Company on the one hand and the Initial Purchasers on the other
with respect to the statements or omissions or alleged statements or alleged
omissions that resulted in such loss, claim, damage or liability (or action in
respect thereof), as well as any other relevant equitable considerations.

The relative benefits received by the Company on the one hand and the Initial
Purchasers on the other with respect to such offering shall be deemed to be in
the same proportion as the total net proceeds from the offering of the Notes
purchased under this Agreement (before deducting expenses) received by the
Company on the one hand, and the total discounts and commissions received by the
Initial Purchasers with respect to the Notes purchased under this Agreement, on
the other hand, bear to the total gross proceeds from the offering of the Notes
under this Agreement, in each case as set forth in the table on the cover page
of the Offering Memorandum. The relative fault shall be determined by reference
to whether the untrue or alleged untrue statement of a material fact or omission
or alleged omission to state a material fact relates to information supplied by
the Company or the Initial Purchasers, the intent of the parties and their
relative knowledge, access to information and opportunity to correct or prevent
such statement or omission. The Company and the Initial Purchasers agree that it
would not be just and equitable if the amount of contributions pursuant to this
Section 7(d) were to be determined by PRO RATA allocation (even if the Initial
Purchasers were treated as one entity for such purpose) or by any other method
of allocation which does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a
result of the loss, claim, damage or liability, or action in respect thereof,
referred to above in this Section 7(d) shall be deemed to include, for purposes
of this Section 7(d), any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any such action
or claim. Notwithstanding the provisions of this Section 7(d), no Initial
Purchaser shall be required to contribute any amount in excess of the amount by
which the total price at which the

                                       26
<PAGE>

Notes resold by it in the initial placement of such Notes were offered to
investors exceeds the amount of any damages which such Initial Purchaser has
otherwise been required to pay by reason of such untrue or alleged untrue
statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. For purposes of this Section 7(d), each person, if
any, who controls an Initial Purchaser within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act shall have the same rights to
contribution as such Initial Purchaser, and each person, if any, who controls
the Company within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act shall have the same rights to contribution as the Company.
The Initial Purchasers' obligations to contribute as provided in this Section
7(d) are several in proportion to their respective purchase obligations and not
joint.

         (e) The Initial Purchasers severally confirm that the statements (i)
with respect to the offering of the Notes set forth on the cover page of the
Offering Memorandum, (ii) in the fourth paragraph under "Plan of Distribution",
(iii) in the first paragraph under the heading "Plan of
Distribution--Commissions and Discounts" in the Offering Memorandum; (iv) in the
paragraph under the heading "Plan of Distribution--Notes Are Not Being
Registered" in the Offering Memorandum; (v) in the third and fourth sentences of
the first paragraph under the heading "Plan of Distribution--New Issue of Notes"
in the Offering Memorandum; and (vi) in the first and third sentences of the
first paragraph under the heading "Plan of Distribution--Price Stabilization and
Short Positions" in the Offering Memorandum are correct and constitute the only
information furnished in writing to the Company by or on behalf of the Initial
Purchasers specifically for inclusion in the Offering Memorandum.

8.   DEFAULTING INITIAL PURCHASERS.

         If, on any Delivery Date, any Initial Purchaser defaults in the
performance of its obligations under this Agreement, the remaining
non-defaulting Initial Purchasers shall be obligated to purchase the aggregate
principal amount of Notes which the defaulting Initial Purchaser agreed but
failed to purchase on such Delivery Date in the respective proportions which the
total aggregate principal amount of Notes set opposite the name of each
remaining non-defaulting Initial Purchaser in Schedule 1 hereto bears to the
total aggregate principal amount of Notes set opposite the names of all the
remaining non-defaulting Initial Purchasers in Schedule 1 hereto; PROVIDED,
HOWEVER, that the remaining non-defaulting Initial Purchasers shall not be
obligated to purchase any Notes on such Delivery Date if the total aggregate
principal amount of Notes which the defaulting Initial Purchasers agreed but
failed to purchase on such date exceeds 9.09% of the total aggregate principal
amount at maturity of Notes to be purchased on such Delivery Date, and any
remaining non-defaulting Initial Purchaser shall not be obligated to purchase
more than 110% of the aggregate principal amount at maturity of Notes which it
agreed to purchase on such Delivery Date pursuant to the terms of Section 2. If
the foregoing maximums are exceeded, the remaining non-defaulting Initial
Purchasers, or those other purchasers satisfactory to the Initial Purchasers who
so agree, shall have the right, but shall not be obligated, to purchase on such
Delivery Date, in such proportion as may be agreed upon among them, the total
aggregate principal amount of Notes to be purchased on such Delivery

                                       27
<PAGE>

Date. If the remaining Initial Purchasers or other purchasers satisfactory to
the Initial Purchasers do not elect to purchase on such Delivery Date the
aggregate principal amount of Notes which the defaulting Initial Purchasers
agreed but failed to purchase, this Agreement (or with respect to the Optional
Delivery Date, the obligation of the Initial Purchasers to purchase the Optional
Notes) shall terminate without liability on the part of any non-defaulting
Initial Purchasers and the Company, except that the Company will continue to be
liable for the payment of expenses to the extent set forth in Sections 4 and 10.
As used in this Agreement, the term "Initial Purchaser" includes, for all
purposes of this Agreement unless the context requires otherwise, any party not
listed in Schedule 1 hereto who, pursuant to this Section 8, purchases Notes
which a defaulting Initial Purchaser agreed but failed to purchase.

         Nothing contained herein shall relieve a defaulting Initial Purchaser
of any liability it may have to the Company for damages caused by its default.
If other purchasers are obligated or agree to purchase the Notes of a defaulting
or withdrawing Initial Purchaser, either the remaining non-defaulting Initial
Purchasers or the Company may postpone the Delivery Date for up to seven full
business days in order to effect any changes in the Offering Memorandum or in
any other document or arrangement that, in the opinion of counsel to the Company
or counsel to the Initial Purchasers, may be necessary.

9.   TERMINATION.

         (a) The obligations of the Initial Purchasers hereunder may be
terminated by the Initial Purchasers by notice given to and received by the
Company prior to delivery of and payment for the Notes if, prior to that time:
(i) there has occurred one of the events described in Section 5(L), or (ii)
there has occurred any material adverse change in the financial markets in the
United States, any outbreak of hostilities or escalation thereof or other
calamity or crisis or any change or development involving a prospective change
in national or international political, financial or economic conditions, in
each case the effect of which is such as to make it, in the judgment of the
Representatives, impracticable to market the Notes or to enforce contracts for
the sale of the Notes, or (iii) trading in any securities of the Company has
been suspended or materially limited by the Commission or the Nasdaq National
Market, or if trading generally on the American Stock Exchange or the New York
Stock Exchange or in The Nasdaq Stock Market has been suspended or materially
limited, or minimum or maximum prices for trading have been fixed, or maximum
ranges for prices have been required, by any of said exchanges or by such system
or by order of the Commission, the National Association of Securities Dealers,
Inc. or any other governmental authority, or (iv) a banking moratorium has been
declared by either Federal or New York authorities.

         (b) If this Agreement is terminated pursuant to this Section 9, such
termination shall be without liability of any party to any other party except as
provided in Section 10.

10. REIMBURSEMENT OF INITIAL PURCHASERS' EXPENSES. If (a) the Company shall fail
to tender the Notes for delivery to the Initial Purchasers for any reason
permitted under this Agreement or (b) the Initial Purchasers shall decline to
purchase the Notes for any reason permitted under this Agreement (including the
termination of this Agreement pursuant to Section 9), the Company

                                       28
<PAGE>

shall reimburse the Initial Purchasers for the fees and expenses of their
counsel and for such other out-of-pocket expenses as shall have been incurred by
them in connection with this Agreement and the proposed purchase of the Notes,
and upon demand the Company shall pay the full amount thereof to the Initial
Purchasers. If this Agreement is terminated pursuant to Section 8 by reason of
the default of one or more Initial Purchasers, the Company shall not be
obligated to reimburse any defaulting Initial Purchaser on account of those
expenses.

11. NOTICES, ETC. All statements, requests, notices and agreements hereunder
shall be in writing, and:

         (a) if to the Initial Purchasers, shall be delivered or sent by mail,
telex or facsimile transmission to c/o Merrill Lynch & Co., North Tower, World
Financial Center, New York, New York 10281, Attention: Paul A. Pepe (Fax:
212-738-1069); and

         (b) if to the Company, shall be delivered or sent by mail, telex or
facsimile transmission to Inhale Therapeutic Systems, Inc., 150 Industrial Road,
San Carlos, California 94070, Attention: Stephen L. Hurst, Esq.
(Fax: 650-631-3150).

PROVIDED, HOWEVER, that any notice to an Initial Purchaser pursuant to Section
7(c) shall be delivered or sent by mail, telex or facsimile transmission to each
such Initial Purchaser, which address will be supplied to any other party hereto
by Lehman Brothers Inc. upon request. Any such statements, requests, notices or
agreements shall take effect at the time of receipt thereof. The Company shall
be entitled to act and rely upon any request, consent, notice or agreement given
or made on behalf of the Initial Purchasers by Merrill Lynch.

12. PERSONS ENTITLED TO BENEFIT OF AGREEMENT. This Agreement shall inure to the
benefit of and be binding upon the Initial Purchasers, the Company and their
respective successors. This Agreement and the terms and provisions hereof are
for the sole benefit of only those persons, except that the representations,
warranties, indemnities and agreements of the Company contained in this
Agreement shall also be deemed to be for the benefit of the officers and
employees of each Initial Purchaser and the person or persons, if any, who
control each Initial Purchaser within the meaning of Section 15 of the
Securities Act and any indemnity agreement of the Initial Purchasers contained
in Section 7(b) of this Agreement shall be deemed to be for the benefit of
directors, officers and employees of the Company, and any person controlling the
Company within the meaning of Section 15 of the Securities Act. Nothing
contained in this Agreement is intended or shall be construed to give any
person, other than the persons referred to in this Section 12, any legal or
equitable right, remedy or claim under or in respect of this Agreement or any
provision contained herein.

13. SURVIVAL. The respective indemnities, representations, warranties and
agreements of the Company and the Initial Purchasers contained in this Agreement
or made by or on behalf of them, respectively, pursuant to this Agreement, shall
survive the delivery of and payment for the Notes and shall remain in full force
and effect, regardless of any termination or cancellation of this Agreement or
any investigation made by or on behalf of any of them or any person controlling
any of them.

                                       29
<PAGE>

14. DEFINITION OF THE TERMS "BUSINESS DAY" AND "SUBSIDIARY". For purposes of
this Agreement, (a) "business day" means any day on which the New York Stock
Exchange, Inc. is open for trading and (b) "subsidiary" has the meaning set
forth in Rule 405 of the rules and regulations promulgated under the Securities
Act.

15. GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

16. COUNTERPARTS. This Agreement may be executed in one or more counterparts
and, if executed in more than one counterpart, the executed counterparts shall
each be deemed to be an original but all such counterparts shall together
constitute one and the same instrument.

17. HEADINGS. The headings herein are inserted for convenience of reference only
and are not intended to be part of, or to affect the meaning or interpretation
of, this Agreement.

                                       30
<PAGE>

         If the foregoing correctly sets forth the agreement between the Company
and the Initial Purchasers, please indicate your acceptance in the space
provided for that purpose below.

                                              Very truly yours,

                                              INHALE THERAPEUTIC SYSTEMS, INC.

                                              By:
                                                 -------------------------------
                                                   Name:
                                                   Title:

Accepted and agreed by:

MERRILL LYNCH & CO.
MERRILL LYNCH, PIERCE, FENNER & SMITH
                      INCORPORATED
DEUTSCHE BANK SECURITIES INC.
LEHMAN BROTHERS INC.
U.S. BANCORP PIPER JAFFRAY INC.

By:   MERRILL LYNCH, PIERCE, FENNER & SMITH
                            INCORPORATED

      By:
         ----------------------------------
             Authorized Representative

                                       31
<PAGE>

                                   SCHEDULE 1

<TABLE>
<CAPTION>

                                                                          PRINCIPAL AMOUNT
      INITIAL PURCHASERS                                                    OF FIRM NOTES
      ------------------                                                    -------------
<S>                                                                          <C>
      Merrill Lynch, Pierce, Fenner & Smith
                     Incorporated ...........................................$66,000,000
      Deutsche Bank Securities Inc...........................................$66,000,000
      Lehman Brothers Inc. ..................................................$48,000,000
      U.S. Bancorp Piper Jaffray Inc.........................................$20,000,000

           Total............................................................$200,000,000
</TABLE><PAGE>

                        RESALE REGISTRATION RIGHTS AGREEMENT

                                       among

                         INHALE THERAPEUTIC SYSTEMS, INC.,

                                MERRILL LYNCH & CO.,
                 MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED

                           DEUTSCHE BANK SECURITIES INC.

                                LEHMAN BROTHERS INC.

                                        and

                          U.S. BANCORP PIPER JAFFRAY INC.

                            Dated as of February 8, 2000

<PAGE>

     Resale Registration Rights Agreement (the "Agreement"), dated as of
February 8, 2000 among Inhale Therapeutic Systems, Inc., a Delaware corporation
(together with any successor entity, herein referred to as the "Issuer"),
Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated,
Deutsche Bank Securities Inc., Lehman Brothers Inc., and U.S. Bancorp Piper
Jaffray Inc. (collectively, the "Initial Purchasers").

     Pursuant to the Purchase Agreement, dated February 2, 2000, between the
Issuer and the Initial Purchasers (the "Purchase Agreement"), the Initial
Purchasers have agreed to purchase from the Issuer up to $200,000,000
($230,000,000 if the Initial Purchasers exercise the over-allotment option in
full) in aggregate principal amount of 5% Convertible Subordinated Notes due
2007 (the "Notes").  The Notes will be convertible into fully paid,
nonassessable common stock, par value $.0001 per share, of the Issuer  (the
"Common Stock") on the terms, and subject to the conditions, set forth in the
Indenture (as defined herein).  To induce the Initial Purchasers to purchase the
Notes, the Issuer has agreed to provide the registration rights set forth in
this Agreement pursuant to Section 3(l) of the Purchase Agreement.

     The parties hereby agree as follows:

     1.   DEFINITIONS.  As used in this Agreement, the following capitalized
terms shall have the following meanings:

     ADVICE:  As defined in Section 4(c)(ii) hereof.

     AGREEMENT:  As defined in the preamble hereto.

     BLUE SKY APPLICATION:  As defined in Section 6(a) hereof.

     BROKER-DEALER:  Any broker or dealer registered under the Exchange Act.

     BUSINESS DAY:  A day other than a Saturday or Sunday or any federal holiday
in the United States.

     CLOSING DATE:  The date of this Agreement.

     COMMISSION:  Securities and Exchange Commission.

     COMMON STOCK:  As defined in the preamble hereto.

     DAMAGES PAYMENT DATE:  Each Interest Payment Date.  For purposes of this
Agreement, if no Notes are outstanding, "Damages Payment Date" shall mean each
February 8 and August 8.

     EFFECTIVENESS PERIOD:  As defined in Section 2(a)(iii) hereof.

     EFFECTIVENESS TARGET DATE:  As defined in Section 2(a)(ii) hereof.

     EXCHANGE ACT:  Securities Exchange Act of 1934, as amended.

                                          1.

<PAGE>

     HOLDER:  A Person who owns, beneficially or otherwise, Transfer Restricted
Securities.

     INDEMNIFIED HOLDER:  As defined in Section 6(a) hereof.

     INDENTURE:  The Indenture, dated as of February 8, 2000, between the Issuer
and  Chase Manhattan Bank and Trust Company, National Association, as trustee
(the "Trustee"), pursuant to which the Notes are to be issued, as such Indenture
is amended, modified or supplemented from time to time in accordance with the
terms thereof.

     INITIAL PURCHASERS:  As defined in the preamble hereto.

     INTEREST PAYMENT DATE:  As defined in the Indenture.

     ISSUER:  As defined in the preamble hereto.

     LIQUIDATED DAMAGES:  As defined in Section 3(a) hereof.

     MAJORITY OF HOLDERS:  Holders holding over 50% of the aggregate principal
amount of Notes outstanding; provided that, for purpose of this definition, a
holder of shares of Common Stock which constitute Transfer Restricted Securities
and were issued upon conversion of the Notes shall be deemed to hold an
aggregate principal amount of Notes (in addition to the aggregate principal
amount of Notes held by such holder) equal to the aggregate principal amount of
Notes converted by such Holder into such shares of Common Stock.

     NASD:  National Association of Securities Dealers, Inc.

     NOTES:  As defined in the preamble hereto.

     PERSON:  An individual, partnership, corporation, unincorporated
organization, trust, joint venture or a government or agency or political
subdivision thereof.

     PROSPECTUS:  The prospectus included in a Shelf Registration Statement, as
amended or supplemented by any prospectus supplement and by all other amendments
thereto, including post-effective amendments, and all material incorporated by
reference into such Prospectus.

     QUESTIONNAIRE DEADLINE:  As defined in Section 2(b) hereof.

     RECORD HOLDER:  With respect to any Damages Payment Date, each Person who
is a Holder on the record date with respect to the Interest Payment Date on
which such Damages Payment Date shall occur.  In the case of a Holder of shares
of Common Stock issued upon conversion of the Notes, "Record Holder" shall mean
each Person who is a Holder of shares of Common Stock which constitute Transfer
Restricted Securities on the January 24 or July 24 immediately preceding the
Damages Payment Date.

     REGISTRATION DEFAULT:  As defined in Section 3(a) hereof.

                                          2.

<PAGE>

     SALE NOTICE:  As defined in Section 4(e) hereof.

     SECURITIES ACT:  Securities Act of 1933, as amended.

     SHELF FILING DEADLINE: As defined in Section 2(a)(i) hereof.

     SHELF REGISTRATION STATEMENT:  As defined in Section 2(a)(i) hereof.

     SUSPENSION PERIOD.  As defined in Section 4(b)(i) hereof.

     TIA:  Trust Indenture Act of 1939, as in effect on the date the Indenture
is qualified under the TIA.

     TRANSFER RESTRICTED SECURITIES:  Each Note and each share of Common Stock
issued upon conversion of Notes until the earlier of:

          (i)   the date on which such Note or such share of Common Stock issued
     upon conversion has been effectively registered under the Securities Act
     and disposed of in accordance with the Shelf Registration Statement;

          (ii)  the date on which such Note or such share of Common Stock issued
     upon conversion is transferred in compliance with Rule 144 under the
     Securities Act or may be sold or transferred pursuant to Rule 144 under the
     Securities Act (or any other similar provision then in force); or

          (iii) the date on which such Note or such share of Common Stock issued
     upon conversion ceases to be outstanding (whether as a result of
     redemption, repurchase and cancellation, conversion or otherwise).

     UNDERWRITTEN REGISTRATION OR UNDERWRITTEN OFFERING:  A registration in
which securities of the Issuer are sold to an underwriter for reoffering to the
public.

     2.   SHELF REGISTRATION.

     (a)  The Issuer shall:

          (i)   not later than 90 days after the date hereof (the "Shelf Filing
     Deadline"), cause to be filed a registration statement pursuant to Rule 415
     under the Securities Act (the "Shelf Registration Statement"), which Shelf
     Registration Statement shall provide for resales of all Transfer Restricted
     Securities held by Holders that have provided the information required
     pursuant to the terms of Section 2(b) hereof;

          (ii)  use its best efforts to cause the Shelf Registration Statement
     to be declared effective by the Commission as promptly as reasonably
     practicable, but in no event later than 180 days after the date hereof (the
     "Effectiveness Target Date"); and

                                          3.

<PAGE>

          (iii) use its best efforts to keep the Shelf Registration Statement
     continuously effective, supplemented and amended as required by the
     provisions of Section 4(b) hereof to the extent necessary to ensure that
     (A) it is available for resales by the Holders of Transfer Restricted
     Securities entitled to the benefit of this Agreement and (B) conforms with
     the requirements of this Agreement and the Securities Act and the rules and
     regulations of the Commission promulgated thereunder as announced from time
     to time for a period (the "Effectiveness Period") of:

                (1) two years following the last date of original issuance of
          Notes; or

                (2) such shorter period that will terminate when (x) all of the
          Holders of Transfer Restricted Securities are able to sell all
          Transfer Restricted Securities immediately without restriction
          pursuant to Rule 144(k) under the Securities Act or any successor rule
          thereto, (y) when all Transfer Restricted Securities have ceased to be
          outstanding (whether as a result of redemption, repurchase and
          cancellation, conversion or otherwise) or (z) all Transfer Restricted
          Securities registered under the Shelf Registration Statement have been
          sold.

     (b)  No Holder of Transfer Restricted Securities may include any of its
Transfer Restricted Securities in the Shelf Registration Statement pursuant to
this Agreement unless such Holder furnishes to the Issuer in writing, prior to
or on the 20th Business Day after receipt of a request therefor (the
"Questionnaire Deadline"), such information as the Issuer may reasonably request
for use in connection with the Shelf Registration Statement or the Prospectus or
preliminary Prospectus included therein and in any application to be filed with
or under state securities laws.  In connection with all such requests for
information from Holders of Transfer Restricted Securities, the Issuer shall
notify such Holders of the requirements set forth in the preceding sentence.  No
Holder of Transfer Restricted Securities shall be entitled to Liquidated Damages
pursuant to Section 3 hereof unless such Holder shall have provided all such
reasonably requested information prior to or on the Questionnaire Deadline.
Each Holder as to which the Shelf Registration Statement is being effected
agrees to furnish promptly to the Issuer all information required to be
disclosed in order to make information previously furnished to the Issuer by
such Holder not materially misleading.

     3.   LIQUIDATED DAMAGES.

     (a)  If:

          (i)   the Shelf Registration Statement is not filed with the
     Commission prior to or on the Shelf Filing Deadline;

          (ii)  the Shelf Registration Statement has not been declared effective
     by the Commission prior to or on the Effective Target Date;

          (iii) subject to the provisions of Section 4(b)(i) hereof, the Shelf
     Registration Statement is filed and declared effective but, during the
     Effectiveness Period, shall thereafter cease to be effective or fail to be
     usable for its intended purpose without being succeeded within five
     Business Days by a post-effective amendment to the Shelf Registration
     Statement or a report filed with the Commission pursuant to Section 13(a),

                                          4.

<PAGE>

     13(c), 14 or 15(d) of the Exchange Act that cures such failure and, in the
     case of a post-effective amendment, is itself immediately declared
     effective; or

          (iv)  prior to or on the 45th or 60th day, as the case may be, of any
     Suspension Period, such suspension has not been terminated,

     (each such event referred to in foregoing clauses (i) through (iv), a
     "Registration Default"), the Issuer hereby agrees to pay liquidated damages
     ("Liquidated Damages") with respect to the Transfer Restricted Securities
     from and including the day following the Registration Default to but
     excluding the day on which the Registration Default has been cured:

                (A) in respect of the Notes, to each holder of Notes, (x) with
          respect to the first 90-day period during which a Registration Default
          shall have occurred and be continuing, in an amount per year equal to
          an additional 0.25% of the principal amount of the Notes, and (y) with
          respect to the period commencing on the 91st day following the day the
          Registration Default shall have occurred and be continuing, in an
          amount per year equal to an additional 0.50% of the principal amount
          of the Notes; provided that in no event shall Liquidated Damages
          accrue at a rate per year exceeding 0.50% of the principal amount of
          the Notes; and

                (B) in respect of any shares of Common Stock, to each holder of
          shares of Common Stock issued upon conversion of Notes, (x) with
          respect to the first 90-day period in which a Registration Default
          shall have occurred and be continuing, in an amount per year equal to
          0.25% of the principal amount of the converted Notes, and (y) with
          respect to the period commencing the 91st day following the day the
          Registration Default shall have occurred and be continuing, in an
          amount per year equal to 0.50% of the principal amount of the
          converted Notes; provided that in no event shall Liquidated Damages
          accrue at a rate per year exceeding 0.50% of the principal amount of
          the converted Notes.

     (b)  All accrued Liquidated Damages shall be paid in arrears to Record
Holders by the Issuer on each Damages Payment Date by wire transfer of
immediately available funds or by federal funds check.  Following the cure of
all Registration Defaults relating to any particular Note or share of Common
Stock, the accrual of Liquidated Damages with respect to such Note or share of
Common Stock will cease.

     All obligations of the Issuer set forth in this Section 3 that are
outstanding with respect to any Transfer Restricted Security at the time such
security ceases to be a Transfer Restricted Security shall survive until such
time as all such obligations with respect to such Transfer Restricted Security
shall have been satisfied in full.

     The Liquidated Damages set forth above shall be the exclusive monetary
remedy available to the Holders of Transfer Restricted Securities for such
Registration Default.

     4.   REGISTRATION PROCEDURES.

                                          5.

<PAGE>

     (a)  In connection with the Shelf Registration Statement, the Issuer shall
comply with all the provisions of Section 4(b) hereof and shall use its best
efforts to effect such registration to permit the sale of the Transfer
Restricted Securities being sold in accordance with the intended method or
methods of distribution thereof, and pursuant thereto, shall as expeditiously as
possible prepare and file with the Commission a Shelf Registration Statement
relating to the registration on any appropriate form under the Securities Act.

     (b)  In connection with the Shelf Registration Statement and any Prospectus
required by this Agreement to permit the sale or resale of Transfer Restricted
Securities, the Issuer shall:

          (i)   Subject to any notice by the Issuer in accordance with this
     Section 4(b) of the existence of any fact or event of the kind described in
     Section 4(b)(iii)(D), use its best efforts to keep the Shelf Registration
     Statement continuously effective during the Effectiveness Period; upon the
     occurrence of any event that would cause the Shelf Registration Statement
     or the Prospectus contained therein (A) to contain a material misstatement
     or omission or (B) not be effective and usable for resale of Transfer
     Restricted Securities during the Effectiveness Period, the Issuer shall
     file promptly an appropriate amendment to the Shelf Registration Statement
     or a report filed with the Commission pursuant to Section 13(a), 13(c), 14
     or 15(d) of the Exchange Act, in the case of clause (A), correcting any
     such misstatement or omission, and, in the case of either clause (A) or
     (B), use its best efforts to cause such amendment to be declared effective
     and the Shelf Registration Statement and the related Prospectus to become
     usable for their intended purposes as soon as practicable thereafter.
     Notwithstanding the foregoing, the Issuer may suspend the effectiveness of
     the Shelf Registration Statement by written notice to the Holders for a
     period not to exceed an aggregate of 45 days in any 90-day period (each
     such period, a "Suspension Period") if:

                (x)   an event occurs and is continuing as a result of which the
          Shelf Registration Statement would, in the Issuer's reasonable
          judgment, contain an untrue statement of a material fact or omit to
          state a material fact required to be stated therein or necessary to
          make the statements therein not misleading; and

                (y)   the Issuer reasonably determines that the disclosure of
          such event at such time would have a material adverse effect on the
          business of the Issuer (and its subsidiaries, if any, taken as a
          whole);

PROVIDED that in the event the disclosure relates to a previously undisclosed
proposed or pending material business transaction, the disclosure of which would
impede the Issuer's ability to consummate such transaction, the Issuer may
extend a Suspension Period from 45 days to 60 days; provided, however, that
Suspension Periods shall not exceed an aggregate of 90 days in any 360-day
period.

          (ii)  Prepare and file with the Commission such amendments and
     post-effective amendments to the Shelf Registration Statement as may be
     necessary to keep the Shelf Registration Statement effective during the
     Effectiveness Period; cause the Prospectus to be supplemented by any
     required Prospectus supplement, and as so supplemented to be filed pursuant
     to Rule 424 under the Securities Act, and to comply fully with the

                                          6.

<PAGE>

     applicable provisions of Rules 424 and 430A under the Securities Act in a
     timely manner; and comply with the provisions of the Securities Act with
     respect to the disposition of all securities covered by the Shelf
     Registration Statement during the applicable period in accordance with the
     intended method or methods of distribution by the sellers thereof set forth
     in the Shelf Registration Statement or supplement to the Prospectus.

          (iii) Advise the underwriter(s), if any, and selling Holders promptly
     (but in any event within five Business Days) and, if requested by such
     Persons, to confirm such advice in writing:

                (A) when the Prospectus or any Prospectus supplement or
          post-effective amendment has been filed, and, with respect to the
          Shelf Registration Statement or any post-effective amendment thereto,
          when the same has become effective,

                (B) of any request by the Commission for amendments to the Shelf
          Registration Statement or amendments or supplements to the Prospectus
          or for additional information relating thereto,

                (C) of the issuance by the Commission of any stop order
          suspending the effectiveness of the Shelf Registration Statement under
          the Securities Act or of the suspension by any state securities
          commission of the qualification of the Transfer Restricted Securities
          for offering or sale in any jurisdiction, or the initiation of any
          proceeding for any of the preceding purposes, or

                (D) of the existence of any fact or the happening of any event,
          during the Effectiveness Period, that makes any statement of a
          material fact made in the Shelf Registration Statement, the
          Prospectus, any amendment or supplement thereto, or any document
          incorporated by reference therein untrue, or that requires the making
          of any additions to or changes in the Shelf Registration Statement or
          the Prospectus in order to make the statements therein not misleading.

If at any time the Commission shall issue any stop order suspending the
effectiveness of the Shelf Registration Statement, or any state securities
commission or other regulatory authority shall issue an order suspending the
qualification or exemption from qualification of the Transfer Restricted
Securities under state securities or Blue Sky laws, the Issuer shall use its
reasonable best efforts to obtain the withdrawal or lifting of such order at the
earliest possible time.

          (iv)  Furnish to each of the selling Holders and each of the
     underwriter(s), if any, before filing with the Commission, a copy of the
     Shelf Registration Statement and copies of any Prospectus included therein
     or any amendments or supplements to the Shelf Registration Statement or
     Prospectus (other than documents incorporated by reference after the
     initial filing of the Shelf Registration Statement), which documents will
     be subject to the review of such holders and underwriter(s), if any, for a
     period of at least ten Business Days, and the Issuer will not file any
     Shelf Registration Statement or Prospectus or any amendment or supplement
     to the Shelf Registration Statement or Prospectus (other than documents
     incorporated by reference) to which a selling Holder of Transfer

                                          7.

<PAGE>

     Restricted Securities covered by the Shelf Registration Statement or the
     underwriter(s), if any, shall reasonably object within five Business Days
     after the receipt thereof.  A selling Holder or underwriter, if any, shall
     be deemed to have reasonably objected to such filing if the Shelf
     Registration Statement, amendment, Prospectus or supplement, as applicable,
     as proposed to be filed, contains a material misstatement or omission.
     Notwithstanding the foregoing, the Issuer shall not be required to furnish
     the selling Holders with any amendment or supplement to the Shelf
     Registration Statement or Prospectus filed solely to reflect changes to the
     amount of Notes held by any particular Holder at the request of such Holder
     or immaterial revisions to the information contained therein.

          (v)   Make available at reasonable times for inspection by one or more
     representatives of the selling Holders, designated in writing by a Majority
     of Holders whose Transfer Restricted Securities are included in the Shelf
     Registration Statement, any underwriter participating in any distribution
     pursuant to the Shelf Registration Statement, and any attorney or
     accountant retained by such selling Holders or any of the underwriter(s),
     all financial and other records, pertinent corporate documents and
     properties of the Issuer as shall be reasonably necessary to enable them to
     exercise any applicable due diligence responsibilities, and cause the
     Issuer's officers, directors, managers and employees to supply all
     information reasonably requested by any such representative or
     representatives of the selling Holders, underwriter, attorney or accountant
     in connection with the Shelf Registration Statement after the filing
     thereof and before its effectiveness; provided, however, that any
     information designated by the Company as confidential at the time of
     delivery of such information shall be kept confidential by the recipient
     thereof.

          (vi)  If requested by any selling Holders or the underwriter(s), if
     any, promptly incorporate in the Shelf Registration Statement or
     Prospectus, pursuant to a supplement or post-effective amendment if
     necessary, such information as such selling Holders and underwriter(s), if
     any, may reasonably request to have included therein, including, without
     limitation: (1) information relating to the "Plan of Distribution" of the
     Transfer Restricted Securities, (2) information with respect to the
     principal amount of Notes or number of shares of Common Stock being sold to
     such underwriter(s), (3) the purchase price being paid therefor and (4) any
     other terms of the offering of the Transfer Restricted Securities to be
     sold in such offering; and make all required filings of such Prospectus
     supplement or post-effective amendment as soon as reasonably practicable
     after the Issuer is notified of the matters to be incorporated in such
     Prospectus supplement or post-effective amendment.  Notwithstanding the
     foregoing, following the effective date of the Shelf Registration
     Statement, the Issuer shall not be required to file more than one such
     supplement or post-effective amendment to reflect changes in the amount of
     Notes held by any particular Holder at the request of such Holder in any
     30-day period.

          (vii) Furnish to each selling Holder and each of the underwriter(s),
     if any, without charge, at least one copy of the Shelf Registration
     Statement, as first filed with the Commission, and of each amendment
     thereto (and any documents incorporated by reference therein or exhibits
     thereto (or exhibits incorporated in such exhibits by reference) as such
     Person may request).

                                          8.

<PAGE>

          (viii) Deliver to each selling Holder and each of the underwriter(s),
     if any, without charge, as many copies of the Prospectus (including each
     preliminary prospectus) and any amendment or supplement thereto as such
     Persons reasonably may request; subject to any notice by the Issuer in
     accordance with this Section 4(b) of the existence of any fact or event of
     the kind described in Section 4(b)(iii)(D), the Issuer hereby consents to
     the use of the Prospectus and any amendment or supplement thereto by each
     of the selling Holders and each of the underwriter(s), if any, in
     connection with  the offering and the sale of the Transfer Restricted
     Securities covered by the Prospectus or any amendment or supplement
     thereto.

          (ix)   If  an underwriting agreement is entered into and the
     registration is an Underwritten Registration, the Issuer shall:

                 (A)     upon request, furnish to each selling Holder and each
          underwriter, if any, in such substance and scope as they may
          reasonably request and as are customarily made by issuers to
          underwriters in primary underwritten offerings, upon the date of
          closing of any sale of Transfer Restricted Securities in an
          Underwritten Registration:

                    (1)  a certificate, dated the date of such closing, signed
                 by the Chief Financial Officer of the Issuer confirming, as of
                 the date thereof, the matters set forth in Section 5(g) of the
                 Purchase Agreement and such other matters as such parties may
                 reasonably request;

                    (2)  opinions, each dated the date of such closing, of
                 counsel to the Issuer covering such of the matters set forth in
                 Sections 5(c) and 5(d) of the Purchase Agreement as are
                 customarily covered in legal opinions to underwriters in
                 connection with primary underwritten offerings of securities;
                 and

                    (3)  customary comfort letters, dated the date of such
                 closing, from the Issuer's independent certified public
                 accountants (and from any other accountants whose report is
                 contained or incorporated by reference in the Shelf
                 Registration Statement), in the customary form and covering
                 matters of the type customarily covered in comfort letters to
                 underwriters in connection with primary underwritten offerings
                 of securities;

                (B) set forth in full in the underwriting agreement, if any,
          indemnification provisions and procedures which provide rights no less
          protective than those set forth in Section 6 hereof with respect to
          all parties to be indemnified; and

                (C) deliver such other documents and certificates as may be
          reasonably requested by such parties to evidence compliance with
          clause (A) above and with any customary conditions contained in the
          underwriting agreement or other agreement entered into by the selling
          Holders pursuant to this clause (ix).

                                          9.

<PAGE>

          (x)   Before any public offering of Transfer Restricted Securities,
     cooperate with the selling Holders, the underwriter(s), if any, and their
     respective counsel in connection with the registration and qualification of
     the Transfer Restricted Securities under the securities or Blue Sky laws of
     such jurisdictions as the selling Holders or underwriter(s), if any, may
     reasonably request and do any and all other acts or things necessary or
     advisable to enable the disposition in such jurisdictions of the Transfer
     Restricted Securities covered by the Shelf Registration Statement;
     provided, however, that the Issuer shall not be required (A) to register or
     qualify as a foreign corporation or a dealer of securities where it is not
     now so qualified or to take any action that would subject it to the service
     of process in any jurisdiction where it is not now so subject or (B) to
     subject themselves to taxation in any such jurisdiction if they are not now
     so subject.

          (xi)    Cooperate with the selling Holders and the underwriter(s), if
     any, to facilitate the timely preparation and delivery of certificates
     representing Transfer Restricted Securities to be sold and not bearing any
     restrictive legends (unless required by applicable securities laws); and
     enable such Transfer Restricted Securities to be in such denominations and
     registered in such names as the Holders or the underwriter(s), if any, may
     request at least two Business Days before any sale of Transfer Restricted
     Securities made by such underwriter(s).

          (xii)   Use its best efforts to cause the Transfer Restricted
     Securities covered by the Shelf Registration Statement to be registered
     with or approved by such other U.S. governmental agencies or authorities as
     may be necessary to enable the seller or sellers thereof or the
     underwriter(s), if any, to consummate the disposition of such Transfer
     Restricted Securities.

          (xiii)  Subject to Section 4(b)(i) hereof, if any fact or event
     contemplated by Section 4(b)(iii)(D) hereof shall exist or have occurred,
     use its reasonable best efforts to prepare a supplement or post-effective
     amendment to the Shelf Registration Statement or related Prospectus or any
     document incorporated therein by reference or file any other required
     document so that, as thereafter delivered to the purchasers of Transfer
     Restricted Securities, the Prospectus will not contain an untrue statement
     of a material fact or omit to state any material fact required to be stated
     therein or necessary to make the statements therein not misleading.

          (xiv)   Provide CUSIP numbers for all Transfer Restricted Securities
     not later than the effective date of the Shelf Registration Statement and
     provide the Trustee under the Indenture with certificates for the Notes
     that are in a form eligible for deposit with The Depository Trust Company.

          (xv)    Cooperate and assist in any filings required to be made with
     the NASD and in the performance of any due diligence investigation by any
     underwriter that is required to be retained in accordance with the rules
     and regulations of the NASD.

          (xvi)   Otherwise use its best efforts to comply with all applicable
     rules and regulations of the Commission and all reporting requirements
     under the rules and regulations of the Exchange Act.

                                         10.

<PAGE>

          (xvii)  Cause the Indenture to be qualified under the TIA not later
     than the effective date of the Shelf Registration Statement required by
     this Agreement, and, in connection therewith, cooperate with the trustee
     and the holders of Notes to effect such changes to the Indenture as may be
     required for such Indenture to be so qualified in accordance with the terms
     of the TIA; and execute and use its best efforts to cause the trustee
     thereunder to execute all documents that may be required to effect such
     changes and all other forms and documents required to be filed with the
     Commission to enable such Indenture to be so qualified in a timely manner.

          (xviii) Cause all Transfer Restricted Securities covered by the Shelf
     Registration Statement to be listed or quoted, as the case may be, on each
     securities exchange or automated quotation system on which similar
     securities issued by the Issuer are then listed or quoted.

          (xix)   Provide promptly to each Holder upon written request each
     document filed with the Commission pursuant to the requirements of Section
     13 and Section 15 of the Exchange Act after the effective date of the Shelf
     Registration Statement.

          (xx)    If requested by the underwriters, make appropriate officers of
     the Issuer available to the underwriters for meetings with prospective
     purchasers of the Transfer Restricted Securities and prepare and present to
     potential investors customary "road show" material in a manner consistent
     with other new issuances of other securities similar to the Transfer
     Restricted Securities.

     (c)  Each Holder agrees by acquisition of a Transfer Restricted Security
that, upon receipt of any notice from the Issuer of the existence of any fact of
the kind described in Section 4(b)(iii)(D) hereof, such Holder will, and will
use its reasonable best efforts to cause any underwriter(s) in an Underwritten
Offering to, forthwith discontinue disposition of Transfer Restricted Securities
pursuant to the Shelf Registration Statement until:

          (i)     such Holder has received copies of the supplemented or amended
     Prospectus contemplated by Section 4(b)(xiii) hereof; or

          (ii)    such Holder is advised in writing (the "Advice") by the Issuer
     that the use of the Prospectus may be resumed, and has received copies of
     any additional or supplemental filings that are incorporated by reference
     in the Prospectus.

If so directed by the Issuer, each Holder will deliver to the Issuer (at the
Issuer's expense) all copies, other than permanent file copies then in such
Holder's possession, of the Prospectus covering such Transfer Restricted
Securities that was current at the time of receipt of such notice of suspension.

     (d)  Each Holder who intends to be named as a selling Holder in the Shelf
Registration Statement shall furnish to the Issuer in writing, within 20
Business Days after receipt of a request therefor as set forth in a
questionnaire, such information regarding such Holder and the proposed
distribution by such Holder of its Transfer Restricted Securities as the Issuer
may reasonably request for use in connection with the Shelf Registration
Statement or Prospectus or preliminary

                                         11.

<PAGE>

Prospectus included therein.  (The form of the questionnaire is attached hereto
as Exhibit A.)  Holders that do not complete the questionnaire and deliver it to
the Issuer shall not be named as selling securityholders in the Prospectus or
preliminary Prospectus included in the Shelf Registration Statement and
therefore shall not be permitted to sell any Transfer Restricted Securities
pursuant to the Shelf Registration Statement.  Each Holder who intends to be
named as a selling Holder in the Shelf Registration Statement shall promptly
furnish to the Issuer in writing such other information as the Issuer may from
time to time reasonably request in writing.

     (e)  Upon the effectiveness of the Shelf Registration Statement, each
Holder shall notify the Issuer at least three Business Days prior to any
intended distribution of Transfer Restricted Securities pursuant to the Shelf
Registration Statement (a "Sale Notice"), which notice shall be effective for
five Business Days.  Each Holder of this Security, by accepting the same, agrees
to hold any communication by the Company in response to a Sale Notice in
confidence.

     5.   REGISTRATION EXPENSES.

     (a)  All expenses incident to the Issuer's performance of or compliance
with this Agreement shall be borne by the Issuer regardless of whether a Shelf
Registration Statement becomes effective, including, without limitation:

          (i)     all registration and filing fees and expenses (including
     filings made by any Initial Purchasers or Holders with the NASD);

          (ii)    all fees and expenses of compliance with federal securities
     and state Blue Sky or securities laws;

          (iii)   all expenses of printing (including printing of Prospectuses
     and certificates for the Common Stock to be issued upon conversion of the
     Notes), messenger and delivery services and telephone;

          (iv)    all fees and disbursements of counsel to the Issuer and,
     subject to Section 5(b) below, the Holders of Transfer Restricted
     Securities;

          (v)     all application and filing fees in connection with listing (or
     authorizing for quotation) the Common Stock on a national securities
     exchange or automated quotation system pursuant to the requirements hereof;
     and

          (vi)    all fees and disbursements of independent certified public
     accountants of the Issuer (including the expenses of any special audit and
     comfort letters required by or incident to such performance).

     The Issuer shall bear its internal expenses (including, without limitation,
all salaries and expenses of their officers and employees performing legal,
accounting or other duties), the expenses of any annual audit and the fees and
expenses of any Person, including special experts, retained by the Issuer.

     (b)  In connection with the Shelf Registration Statement required by this
Agreement, the Issuer shall reimburse the Initial Purchasers and the Holders of
Transfer Restricted Securities

                                         12.

<PAGE>

being registered pursuant to the Shelf Registration Statement, as applicable,
for the reasonable fees and disbursements of not more than one counsel, which
shall be Brown & Wood LLP, or such other counsel as may be chosen by a Majority
of Holders for whose benefit the Shelf Registration Statement is being prepared.

     6.   INDEMNIFICATION AND CONTRIBUTION.

     (a)  The Issuer shall indemnify and hold harmless each Holder, such
Holder's officers and employees and each person, if any, who controls such
Holder within the meaning of the Securities Act (each, an "Indemnified Holder"),
from and against any loss, claim, damage or liability, joint or several, or any
action in respect thereof (including, but not limited to, any loss, claim,
damage, liability or action relating to resales of the Transfer Restricted
Securities), to which such Indemnified Holder may become subject, insofar as any
such loss, claim, damage, liability or action arises out of, or is based upon:

          (i)     any untrue statement or alleged untrue statement of a material
     fact contained in (A) the Shelf Registration Statement or Prospectus or any
     amendment or supplement thereto or (B) any blue sky application or other
     document or any amendment or supplement thereto prepared or executed by the
     Issuer (or based upon written information furnished by or on behalf of the
     Issuer expressly for use in such blue sky application or other document or
     amendment on supplement) filed in any jurisdiction specifically for the
     purpose of qualifying any or all of the Transfer Restricted Securities
     under the securities law of any state or other jurisdiction (such
     application or document being hereinafter called a "Blue Sky Application");
     or

          (ii)    the omission or alleged omission to state therein any material
     fact required to be stated therein or necessary to make the statements
     therein, in the light of the circumstances under which they were made, not
     misleading,

and shall reimburse each Indemnified Holder promptly upon demand for any legal
or other expenses reasonably incurred by such Indemnified Holder in connection
with investigating or defending or preparing to defend against any such loss,
claim, damage, liability or action as such expenses are incurred; provided,
however, that the Issuer shall not be liable in any such case to the extent that
any such loss, claim, damage, liability or action arises out of, or is based
upon, any untrue statement or alleged untrue statement or omission or alleged
omission made in the Shelf Registration Statement or Prospectus or amendment or
supplement thereto or Blue Sky Application in reliance upon and in conformity
with written information furnished to the Issuer by or on behalf of any Holder
(or its related Indemnified Holder) specifically for use therein.  The foregoing
indemnity agreement is in addition to any liability which the Issuer may
otherwise have to any Indemnified Holder.

     (b)  Each Holder, severally and not jointly, shall indemnify and hold
harmless the Issuer, its officers and employees and each person, if any, who
controls the Issuer within the meaning of the Securities Act, from and against
any loss, claim, damage or liability, joint or several, or any action in respect
thereof, to which the Issuer or any such officer, employee or controlling person
may become subject, insofar as any such loss, claim, damage or liability or
action arises out of, or is based upon:

                                         13.

<PAGE>

          (i)     any untrue statement or alleged untrue statement of any
     material fact contained in the Shelf Registration Statement or Prospectus
     or any amendment or supplement thereto or any Blue Sky Application; or

          (ii)    the omission or the alleged omission to state therein any
     material fact required to be stated therein or necessary to make the
     statements therein, in light of the circumstances under which they were
     made, not misleading,

but in each case only to the extent that such untrue statement or alleged untrue
statement or omission or alleged omission was made in reliance upon and in
conformity with written information furnished to the Issuer by or on behalf of
such Holder (or its related Indemnified Holder) specifically for use therein,
and shall reimburse the Issuer and any such officer, employee or controlling
person promptly upon demand for any legal or other expenses reasonably incurred
by the Issuer or any such officer, employee or controlling person in connection
with investigating or defending or preparing to defend against any such loss,
claim, damage, liability or action as such expenses are incurred.  The foregoing
indemnity agreement is in addition to any liability which any Holder may
otherwise have to the Issuer and any such officer, employee or controlling
person.

     (c)  Promptly after receipt by an indemnified party under this Section 6 of
notice of any claim or the commencement of any action, the indemnified party
shall, if a claim in respect thereof is to be made against the indemnifying
party under this Section 6, notify the indemnifying party in writing of the
claim or the commencement of that action; provided, however, that the failure to
notify the indemnifying party shall not relieve it from any liability which it
may have under this Section 6 except to the extent it has been materially
prejudiced by such failure and, provided, further, that the failure to notify
the indemnifying party shall not relieve it from any liability which it may have
to an indemnified party otherwise than under this Section 6.  If any such claim
or action shall be brought against an indemnified party, and it shall notify the
indemnifying party thereof, the indemnifying party shall be entitled to
participate therein and, to the extent that it wishes, jointly with any other
similarly notified indemnifying party, to assume the defense thereof with
counsel satisfactory to the indemnified party.  After notice from the
indemnifying party to the indemnified party of its election to assume the
defense of such claim or action, the indemnifying party shall not be liable to
the indemnified party under this Section 6 for any legal or other expenses
subsequently incurred by the indemnified party in connection with the defense
thereof other than reasonable costs of investigation; provided, however, that a
Majority of Holders shall have the right to employ a single counsel to represent
jointly a Majority of Holders and their respective officers, employees and
controlling persons who may be subject to liability arising out of any claim in
respect of which indemnity may be sought by a Majority of Holders against the
Issuer under this Section 6, if a Majority of Holders shall have reasonably
concluded that there may be one or more legal defenses available to them and
their respective officers, employees and controling persons that are different
from or additional to those available to the Issuer and its officers, employees
and controlling persons, the fees and expenses of a single separate counsel
shall be paid by the Issuer.  No indemnifying party shall:

                                         14.

<PAGE>

          (i)     without the prior written consent of the indemnified parties
     (which consent shall not be unreasonably withheld) settle or compromise or
     consent to the entry of any judgment with respect to any pending or
     threatened claim, action, suit or proceeding in respect of which
     indemnification or contribution may be sought hereunder (whether or not the
     indemnified parties are actual or potential parties to such claim or
     action) unless such settlement, compromise or consent includes an
     unconditional release of each indemnified party from all liability arising
     out of such claim, action, suit or proceeding, or

          (ii)    be liable for any settlement of any such action effected
     without its written consent (which consent shall not be unreasonably
     withheld), but if settled with its written consent or if there be a final
     judgment for the plaintiff in any such action, the indemnifying party
     agrees to indemnify and hold harmless any indemnified party from and
     against any loss of liability by reason of such settlement or judgment.

     (d)  If the indemnification provided for in this Section 6 shall for any
reason be unavailable or insufficient to hold harmless an indemnified party
under Section 6(a) or 6(b) in respect of any loss, claim, damage or liability
(or action in respect thereof) referred to therein, each indemnifying party
shall, in lieu of indemnifying such indemnified party, contribute to the amount
paid or payable by such indemnified party as a result of such loss, claim,
damage or liability (or action in respect thereof):

          (i)     in such proportion as is appropriate to reflect the relative
     benefits received by the Issuer from the offering and sale of the Transfer
     Restricted Securities on the one hand and a Holder with respect to the sale
     by such Holder of the Transfer Restricted Securities on the other, or

          (ii)    if the allocation provided by clause (6)(d)(i) is not
     permitted by applicable law, in such proportion as is appropriate to
     reflect not only the relative benefits referred to in clause 6(d)(i) but
     also the relative fault of the Issuer on the one hand and the Holders on
     the other in connection with the statements or omissions or alleged
     statements or alleged omissions that resulted in such loss, claim, damage
     or liability (or action in respect thereof), as well as any other relevant
     equitable considerations.

The relative benefits received by the Issuer on the one hand and a Holder on the
other with respect to such offering and such sale shall be deemed to be in the
same proportion as the total net proceeds from the offering of the Notes
purchased under the Purchase Agreement (before deducting expenses) received by
the Issuer as set forth in the table on the cover of the Offering Memorandum,
dated February 2, 2000, on the one hand, bear to the total proceeds received by
such Holder with respect to its sale if Transfer Restricted Securities on the
other.  The relative fault of the parties shall be determined by reference to
whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information
supplied by the Issuer on the one hand or the Holders on the other, the intent
of the parties and their relative knowledge, access to information and
opportunity to correct or prevent such statement or omission.  The Issuer and
each Holder agree that it would not be just and equitable if the amount of
contribution pursuant to this Section 6(d) were determined by pro rata

                                         15.

<PAGE>

allocation or by any other method of allocation that does not take into account
the equitable considerations referred to in the first sentence of this paragraph
(d).  The amount paid or payable by an indemnified party as a result of the
loss, claim, damage or liability, or action in respect thereof, referred to
above in this Section 6 shall be deemed to include, for purposes of this Section
6, any legal or other expenses reasonably incurred by such indemnified party in
connection with investigating or defending or preparing to defend any such
action or claim.  Notwithstanding the provisions of this Section 6, no Holder
shall be required to contribute any amount in excess of the amount by which the
total price at which the Transfer Restricted Securities purchased by it were
resold exceeds the amount of any damages which such Holder has otherwise been
required to pay by reason of any untrue or alleged untrue statement or omission
or alleged omission.  No person guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent
misrepresentation.  The Holders' obligations to contribute as provided in this
Section 6(d) are several and not joint.

     7.   RULE 144A.  In the event the Issuer is not subject to Section 13 or
15(d) of the Exchange Act, the Issuer hereby agrees with each Holder, for so
long as any Transfer Restricted Securities remain outstanding, to make available
to any Holder or beneficial owner of Transfer Restricted Securities in
connection with any sale thereof and any prospective purchaser of such Transfer
Restricted Securities from such Holder or beneficial owner, the information
required by Rule 144A(d)(4) under the Securities Act in order to permit resales
of such Transfer Restricted Securities pursuant to Rule 144A.

     8.   PARTICIPATION IN UNDERWRITTEN REGISTRATIONS.  No Holder may
participate in any Underwritten Registration hereunder unless such Holder:

          (i)     agrees to sell such Holder's Transfer Restricted Securities on
     the basis provided in any underwriting arrangements approved by the Persons
     entitled hereunder to approve such arrangements and

          (ii)    completes and executes all reasonable questionnaires, powers
     of attorney, indemnities, underwriting agreements, lock-up letters and
     other documents required under the terms of such underwriting arrangements.

     9.   SELECTION OF UNDERWRITERS.  The Holders of Transfer Restricted
Securities covered by the Shelf Registration Statement who desire to do so may
sell such Transfer Restricted Securities in an Underwritten Offering.  In any
such Underwritten Offering, the investment banker or investment bankers and
manager or managers that will administer the offering will be selected by a
Majority of Holders whose Transfer Restricted Securities are included in such
offering; provided, that such investment bankers and managers must be reasonably
satisfactory to the Issuer.

     10.  MISCELLANEOUS.

     (a)  REMEDIES.  The Issuer acknowledges and agrees that any failure by the
Issuer to comply with its obligations under Section 2 hereof may result in
material irreparable injury to the Initial Purchasers or the Holders for which
there is no adequate remedy at law, that it will not be

                                         16.

<PAGE>

possible to measure damages for such injuries precisely and that, in the event
of any such failure, the Initial Purchasers or any Holder may obtain such relief
as may be required to specifically enforce the Issuer's obligations under
Section 2 hereof.  The Issuer further agrees to waive the defense in any action
for specific performance that a remedy at law would be adequate.

     (b)  ADJUSTMENTS AFFECTING TRANSFER RESTRICTED SECURITIES.  The Issuer
shall not, directly or indirectly, take any action with respect to the Transfer
Restricted Securities as a class that would adversely affect the ability of the
Holders of Transfer Restricted Securities to include such Transfer Restricted
Securities in a registration undertaken pursuant to this Agreement.

     (c)  NO INCONSISTENT AGREEMENTS. The Issuer will not, on or after the date
of this Agreement, enter into any agreement with respect to its securities that
is inconsistent with the rights granted to the Holders in this Agreement or
otherwise conflicts with the provisions hereof.  In addition, the Issuer shall
not grant to any of its security holders (other than the holders of Transfer
Restricted Securities in such capacity) the right to include any of its
securities in the Shelf Registration Statement provided for in this Agreement
other than the Transfer Restricted Securities.  Other than the Stock Purchase
Agreement, dated January 18, 1995, between the Issuer and Pfizer, Inc., the
Stock Purchase Agreement, dated March 1, 1996, as amended, between the Issuer
and Baxter Healthcare Corporation and the Stock Issuance Agreement, dated
November 4, 1999, between the Issuer and Alliance Pharmaceutical Corp., the
Issuer has not previously entered into any agreement (which has not expired or
been terminated) granting any registration rights with respect to its securities
to any Person which rights conflict with the provisions hereof.

     (d)  AMENDMENTS AND WAIVERS. This Agreement may not be amended, modified or
supplemented, and waivers or consents to or departures from the provisions
hereof may not be given, unless the Issuer has obtained the written consent of a
Majority of Holders.

     (e)  NOTICES. All notices and other communications provided for or
permitted hereunder shall be made in writing by hand-delivery, first-class mail
(registered or certified, return receipt requested), telex, telecopier, or air
courier guaranteeing overnight delivery:

          (i)     if to a Holder, at the address set forth on the records of the
     registrar under the Indenture or the transfer agent of the Common Stock, as
     the case may be; and

          (ii)    if to the Issuer:

                         Inhale Therapeutic Systems, Inc.
                         150 Industrial Road
                         San Carlos, California 94070
                         Attention: Stephen L. Hurst, Esq.

                         With a copy to:

                         Cooley Godward LLP
                         3000 Sand Hill Road
                         Building #3, Suite 230

                                         17.

<PAGE>

                         Menlo Park, California  94025
                         Attention:  Marc P. Tanoury, Esq.

     All such notices and communications shall be deemed to have been duly
given: at the time delivered by hand, if personally delivered; five Business
Days after being deposited in the mail, postage prepaid, if mailed; when
answered back, if telexed; when receipt acknowledged, if telecopied; and on the
next Business Day, if timely delivered to an air courier guaranteeing overnight
delivery.

     (f)  SUCCESSORS AND ASSIGNS. This Agreement shall inure to the benefit of
and be binding upon the successors and assigns of each of the parties, including
without limitation and without the need for an express assignment, subsequent
Holders of Transfer Restricted Securities; provided, however, that (i) this
Agreement shall not inure to the benefit of or be binding upon a successor or
assign of a Holder unless and to the extent such successor or assign acquired
Transfer Restricted Securities from such Holder and (ii) nothing contained
herein shall be deemed to permit any assignment, transfer or other disposition
of Transfer Restricted Securities in violation of the terms of the Purchase
Agreement or the Indenture.  If any transferee of any Holder shall acquire
Transfer Restricted Securities, in any manner, whether by operation of law or
otherwise, such Transfer Restricted Securities shall be held subject to all of
the terms of this Agreement, and by taking and holding such Transfer Restricted
Securities such person shall be conclusively deemed to have agreed to be bound
by and to perform all of the terms and provisions of this Agreement.

     (g)  COUNTERPARTS. This Agreement may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which
when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same agreement.

     (h)  SECURITIES HELD BY THE ISSUER OR THEIR AFFILIATES.  Whenever the
consent or approval of Holders of a specified percentage of Transfer Restricted
Securities is required hereunder, Transfer Restricted Securities held by the
Issuer or its "affiliates" (as such term is defined in Rule 405 under the
Securities Act) shall not be counted in determining whether such consent or
approval was given by the Holders of such required percentage.

     (i)  HEADINGS. The headings in this Agreement are for convenience of
reference only and shall not limit or otherwise affect the meaning hereof.

     (j)  GOVERNING LAW.  This Agreement shall be governed by, and construed in
accordance with, the law of the State of New York, without regard to conflict of
laws principles thereof.

     (k)  SEVERABILITY. If  any one or more of the provisions contained herein,
or the application thereof in any circumstance, is held invalid, illegal or
unenforceable, the validity, legality and enforceability of any such provision
in every other respect and of the remaining provisions contained herein shall
not be affected or impaired thereby.

                                         18.

<PAGE>

     (l)  ENTIRE AGREEMENT.  This Agreement is intended by the parties as a
final expression of their agreement and intended to be a complete and exclusive
statement of the agreement and understanding of the parties hereto in respect of
the subject matter contained herein.  There are no restrictions, promises,
warranties or undertakings, other than those set forth or referred to herein
with respect to the registration rights granted by the Issuer with respect to
the Transfer Restricted Securities.  This Agreement supersedes all prior
agreements and understandings between the parties with respect to such subject
matter.

                                         19.

<PAGE>

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first written above.

                                        INHALE THERAPEUTIC SYSTEMS, INC.

                                        By______________________________
                                           Name:
                                           Title:

                                        MERRILL LYNCH, PIERCE, FENNER & SMITH
                                                  INCORPORATED
                                        DEUTSCHE BANK SECURITIES INC.
                                        LEHMAN BROTHERS INC.
                                        U.S. BANCORP PIPER JAFFRAY INC.

                                        By: Merrill Lynch, Pierce, Fenner &
                                                  Smith Incorporated

                                        By_____________________________
                                            Authorized Signatory

                                         20.

<PAGE>

                                                                       EXHIBIT A

                          INHALE THERAPEUTIC SYSTEMS, INC.

              FORM OF SELLING SECURITYHOLDER NOTICE AND QUESTIONNAIRE

     The undersigned beneficial holder of 5% Convertible Subordinated Notes due
2007 (the "Notes") of Inhale Therapeutic Systems, Inc. (the "Issuer"), or common
stock, par value $.001 per share (the "Shares" and together with the Notes, the
"Transfer Restricted Securities") of the Issuer understands that the Issuer has
filed, or intends to file, with the Securities and Exchange Commission (the
"Commission") a registration statement (the "Shelf Registration Statement"), for
the registration and resale under Rule 415 of the Securities Act of 1933, as
amended (the "Securities Act"), of the Transfer Restricted Securities in
accordance with the terms of the Registration Rights Agreement, dated as of
February 8, 2000 (the "Registration Rights Agreement") between the Issuer and
Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Lehman
Brothers Inc., Deutsche Bank Securities Inc. and U.S. Bancorp Piper Jaffray Inc.
A copy of the Registration Rights Agreement is available from the Issuer upon
request at the address set forth below.  All capitalized terms not otherwise
defined herein have the meaning ascribed thereto in the Registration Rights
Agreement.

     Each beneficial owner of Transfer Restricted Securities is entitled to the
benefits of the Registration Rights Agreement.  In order to sell or otherwise
dispose of any Transfer Restricted Securities pursuant to the Shelf Registration
Statement, a beneficial owner of Transfer Restricted Securities generally will
be required to be named as a selling securityholder in the related Prospectus,
deliver a Prospectus to purchasers of Transfer Restricted Securities and be
bound by those provisions of the Registration Rights Agreement applicable to
such beneficial owner (including certain indemnification provisions, as
described below).  BENEFICIAL OWNERS THAT DO NOT COMPLETE THIS NOTICE AND
QUESTIONNAIRE WITHIN 20 BUSINESS DAYS OF RECEIPT HEREOF AND DELIVER IT TO THE
ISSUER AS PROVIDED BELOW WILL NOT BE NAMED AS SELLING SECURITYHOLDERS IN THE
PROSPECTUS AND THEREFORE WILL NOT BE PERMITTED TO SELL ANY TRANSFER RESTRICTED
SECURITIES PURSUANT TO THE SHELF REGISTRATION STATEMENT.

     Certain legal consequences arise from being named as a selling
securityholder in the Shelf Registration Statement and the related Prospectus.
Accordingly, holders and beneficial owners of Transfer Restricted Securities are
advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling securityholder in the Shelf
Registration Statement and the related Prospectus.

                                       NOTICE

     The undersigned beneficial owner (the "Selling Securityholder") of Transfer
Restricted Securities hereby gives notice to the Issuer of its intention to sell
or otherwise dispose of Transfer Restricted Securities beneficially owned by it
and listed below in Item 3 (unless otherwise specified under Item 3) pursuant to
the Shelf Registration Statement.  The

                                          1.

<PAGE>

undersigned, by signing and returning this Notice and Questionnaire, understands
that it will be bound by the terms and conditions of this Notice and
Questionnaire and the Registration Rights Agreement.

     Pursuant to the Registration Rights Agreement, the undersigned has agreed
to indemnify and hold harmless the Issuer, the Issuer's directors, the Issuer's
officers who sign the Shelf Registration Statement and each person, if any, who
controls the Issuer within the meaning of either Section 15 of the Securities
Act or Section 20 of the Exchange Act, from and against certain losses arising
in connection with statements concerning the undersigned made in the Shelf
Registration Statement or the related Prospectus in reliance upon the
information provided in this Notice and Questionnaire.

     The undersigned hereby provides the following information to the Issuer and
represents and warrants that such information is accurate and complete:

                                   QUESTIONNAIRE

1.   (a)  Full legal name of Selling Securityholder:

     (b)  Full legal name of registered holder (if not the same as (a) above)
          through which Transfer Restricted Securities listed in (3) below are
          held:

     (c)  Full legal name of DTC participant (if applicable and if not the same
          as (b) above) through which Transfer Restricted Securities listed in
          (3) are held:

2.   Address for notices to Selling Securityholders:

     Telephone:

     Fax:

     Contact Person:

3.   Beneficial ownership of Transfer Restricted Securities:

     (a)  Type of Transfer Restricted Securities beneficially owned, and
          principal amount of Notes or number of shares of Common Stock, as the
          case may be, beneficially owned:

     (b)  CUSIP No(s). of such Transfer Restricted Securities beneficially
          owned:

                                          2.

<PAGE>

4.   Beneficial ownership of the Issuer's securities owned by the Selling
Securityholder:

     EXCEPT AS SET FORTH BELOW IN THIS ITEM (4), THE UNDERSIGNED IS NOT THE
     BENEFICIAL OR REGISTERED OWNER OF ANY SECURITIES OF THE ISSUER OTHER THAN
     THE TRANSFER RESTRICTED SECURITIES LISTED ABOVE IN ITEM (3) ("OTHER
     SECURITIES").

     (a)   Type and amount of Other Securities beneficially owned by the Selling
           Securityholder:

     (b)   CUSIP No(s). of such Other Securities beneficially owned:

5.   Relationship with the Issuer

     Except as set forth below, neither the undersigned nor any of its
     affiliates, officers, directors or principal equity holders (5% or more)
     has held any position or office or has had any other material relationship
     with the Issuer (or their predecessors or affiliates) during the past three
     years.

     State any exceptions here:

6.   Plan of Distribution

     Except as set forth below, the undersigned (including its donees or
     pledgees) intends to distribute the Transfer Restricted Securities listed
     above in Item (3) pursuant to the Shelf Registration Statement only as
     follows (if at all).  Such Transfer Restricted Securities may be sold from
     time to time directly by the undersigned or, alternatively, through
     underwriters, broker-dealers or agents.  If the Transfer Restricted
     Securities are sold through underwriters or broker-dealers, the Selling
     Securityholder will be responsible for underwriting discounts or
     commissions or agent's commissions.  Such Transfer Restricted Securities
     may be sold in one or more transactions at fixed prices, at prevailing
     market prices at the time of sale, at varying prices determined at the time
     of sale, or at negotiated prices.  Such sales may be effected in
     transactions (which may involve crosses or block transactions):

     (i)   on any national securities exchange or quotation service on which the
Transfer Restricted Securities may be listed or quoted at the time of sale;

     (ii)  in the over-the-counter market;

     (iii) in transactions otherwise than on such exchanges or services or in
     the over-the-counter market; or

                                          3.

<PAGE>

     (iv)  through the writing of options.

In connection with sales of the Transfer Restricted Securities or otherwise, the
undersigned may enter into hedging transactions with broker-dealers, which may
in turn engage in short sales of the Transfer Restricted Securities and deliver
Transfer Restricted Securities to close out such short positions, or loan or
pledge Transfer Restricted Securities to broker-dealers that in turn may sell
such securities.

State any exceptions here:

Note: In no event will such method(s) of distribution take the form of an
underwritten offering of the Transfer Restricted Securities without the prior
agreement of the Issuer.

     The undersigned acknowledges that it understands its obligation to comply
with the provisions of the Exchange Act and the rules and regulations
promulgated thereunder relating to stock manipulation, particularly Regulation M
thereunder (or any successor rules or regulations), in connection with any
offering of Transfer Restricted Securities pursuant to the Shelf Registration
Statement.  The undersigned agrees that neither it nor any person acting on its
behalf will engage in any transaction in violation of such provisions.

     The Selling Securityholder hereby acknowledges its obligations under the
Registration Rights Agreement to indemnify and hold harmless certain persons as
set forth therein.

     Pursuant to the Registration Rights Agreement, the Issuer has agreed under
certain circumstances to indemnify the Selling Securityholders against certain
liabilities.

     In accordance with the undersigned's obligation under the Registration
Rights Agreement to provide such information as may be required by law for
inclusion in the Shelf Registration Statement, the undersigned agrees to
promptly notify the Issuer of any inaccuracies or changes in the information
provided herein that may occur subsequent to the date hereof at any time while
the Shelf Registration Statement remains effective.  All notices hereunder and
pursuant to the Registration Rights Agreement shall be made in writing at the
address set forth below.

     By signing below, the undersigned consents to the disclosure of the
information contained herein in its answers to items (1) through (6) above and
the inclusion of such information in the Shelf Registration Statement and the
related Prospectus. The undersigned understands that such information will be
relied upon by the Issuer in connection with the preparation or amendment of the
Shelf Registration Statement and the related Prospectus.

                                          4.

<PAGE>

     IN WITNESS WHEREOF, the undersigned, by authority duly given, has caused
this Notice and Questionnaire to be executed and delivered either in person or
by its duly authorized agent.

Dated:

Beneficial Owner

By:
   ------------------------------
     Name:
     Title:

Please return the completed and executed Notice and Questionnaire to Inhale
Therapeutic Systems, Inc. at:

           Inhale Therapeutic Systems, Inc.
           150 Industrial Road
           San Carlos, California 94070
           Attention: Stephen L. Hurst, Esq.

                                          5.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]